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Cancer is caused by the accumulation of genetic alterations and consequent disruption of cell 
functions. Over the past decade, the introduction of fast and relatively inexpensive sequencing 
methods has provided unprecedented opportunity to characterize cancer genomic landscapes. 
A variety of bioinformatics tools are now available to discover genetic variations from high 
throughput sequencing of tumor DNA, such as GATK (DePristo et al., 2011), CRISP(Bansal, 
2010), LoFreq (Wilm et al., 2012), VarScan 2 (Koboldt et al., 2012), and SNVer (Z. Wei et al., 
2011), which have been recently evaluated (Pabinger et al., 2014) and (H. W. Huang et al., 
2015). Depending on cancer type, tumors harbor hundreds to tens of thousands of somatic 
mutations, most of which are located in the non-coding portion of the genome (Lawrence et 
al., 2013). However, not all somatic mutations have their contributions to cancer development, 
they are generally divided into two main classes: the „driver‟ and „passenger‟ mutations. The 
former is causally involved in the carcinogenesis, in which it confers selective growth 
advantage to cancer cells and is under positive selection in the cancer microenvironment. The 
latter is the somatic mutation which couldn‟t give growth superiority to cancer cells and 
hasn‟t been positively selected, therefore, it plays little role in cancer formation and 
progression. Driver mutation might not be necessary for the maintenance of the final cancer 
but has to be selected during the cancer-evolving process. Cells which carry driver mutations 
and functionally inert passenger mutations undergo clonal expansion, eventually, forming the 
final cancer (Stratton et al., 2009). Cancer driver genes are genes which carry these driver 
mutations and are critical to cancer formation. They are classified into three main categories: 
(1) genes whose non-synonymous mutation rate is significantly greater than a background 
mutation rate(Lawrence et al., 2013); (2) genes accumulate mutations with high functional 
impact (FM bias) (Gonzalez-Perez and Lopez-Bigas, 2012); (3) genes display a higher rate of 
high-scoring non-synonymous mutations than silent and intronic mutations(Hodis et al., 
2012) . 
A critical challenge in cancer genomics study is to distinguish “driver” mutations and cancer 
genes that are responsible for cancer development upon specific alterations from “passenger” 
mutations that are mere results of the cancerous process. A number of reviews provide 
guidelines for the discovery of cancer-causing variants (MacArthur et al., 2014; Moreau and 
Tranchevent, 2012). The most common strategy is first to prioritize non-synonymous variants 
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in protein-coding regions and then seek recurrently mutated genes in a cohort of cancer 
patients (Chapman et al., 2011; Ding et al., 2008; Gui et al., 2011; Wang et al., 2011; X. Wei 
et al., 2011). Diverse computational methods have been explored to prioritize non-
synonymous variants with respect to their disease-causing potential. Most are based on the 
assumption that coding mutations impacting functionally important residues, as inferred from 
evolutionary conservation and protein domain analysis, are more likely damaging (Vitkup et 
al., 2003). Other software, used in conjunction with these scoring systems, performs 
recurrence search in patient cohorts. Currently, 547 cancer genes are described in the 
COSMIC catalogue of somatic mutations in cancer (version 71) (Forbes et al., 2011a). 
The immense majority of the human genome (98%) is non-coding, and consequently most 
somatic mutations/alterations observed in tumors occur in this non-coding fraction. Because 
non-coding mutations are more difficult to interpret, these regions have been mostly 
discounted from the wider search for driver mutations. However, mutations in non-coding 
regions can have a profound impact on cell fate. Indeed, functional regions in the non-coding 
genome include mRNA splice sites, UTR regulation elements, promoters, transcription factor 
binding sites, enhancers and a wide variety of non-coding RNA (ncRNA) genes. Among 
ncRNA genes, one particular class is now receiving focused attention due to its vast extent: 
long non-coding RNA (lncRNA). According to the latest estimate (Iyer et al., 2015), over 
58,000 lncRNA genes are expressed in the human genome, which makes this class the biggest 
contributor to the “black matter” transcriptome. 
There is ample evidence for disease-related mutations in the non-coding genome. A large 
fraction of disease or trait-relevant single nucleotide polymorphisms (SNPs) detected by 
Genome-wide Association Studies (GWAS) (Beck et al., 2014) is located in the non-coding 
genome, preferentially within enhancers, exons and mRNA promoters (Andersson et al., 
2014). Inherited disease-causing variants are strongly enriched in non-coding regions under 
strong purifying selection, which comprise binding sites of transcription factors (TFs) and 
critical motifs from TF Families (Khurana et al., 2013). Further studies have shown that 
altered ncRNA functions initiated by genetic or regulatory changes play an important role in 
tumorigenesis (Chaluvally-Raghavan et al., 2014; Kwanhian et al., 2012; Ling et al., 2013; 
Ren et al., 2012; Tseng et al., 2014; Wegert et al., 2015). 
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In the absence of a clear and uniform functional code for these highly diverse non-coding 
elements, their variations are much more difficult to interpret than those of amino acid-coding 
regions. In this review we describe the methods and data available to interpret and prioritize 
non-coding genome mutations. As many basic principles in this field were laid for protein-
coding sequence analysis, we start by reviewing the methods developed for scoring protein-
coding variants. We then describe the specific non-coding elements that may be the subject 
cancer-driving mutations and we address the specific methods that were set up to characterize 
these variations. 
1.1 Prioritizing coding variants  
Prioritization of non-synonymous mutations for cancer study is a mature field built upon 
decades of experience in protein sequence and cancer pathway analysis. Table 1 provides a 
listing of the most commonly used tools. We distinguish below three classes of scoring 
systems, using either probabilistic, machine learning or hybrid approaches. 
1.1.1 Probabilistic models 
The pioneering SIFT (Sorting Intolerant From Tolerant) uses sequence homology to predict 
whether an amino acid substitution will affect protein function and hence, potentially alter 
phenotype (Ng and Henikoff, 2003). SIFT identifies conserved protein residues based on 
multiple sequence alignments of homologous proteins and calculates the likelihood that an 
amino acid at a position is tolerated, conditional on the most frequent amino acid being 
tolerated. Mutations in higher conserved coding regions intend to be predicted as more likely 
deleterious than those in lower conserved protein regions. 
The mCluster method (Yue et al., 2010) aggregates mutation data by mapping known disease-
related mutations to positions along conserved domains, and then mapping novel variants to 
those same conserved domains. The program identifies conserved mutation-enriched clusters, 
which are hotspots for cancer driving functional alterations, across multiple proteins. The 
mCluster score is the likelihood of a cluster of certain size occurring, given the number of 
positions in the domain and the mutation frequency. 
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MutationAssessor (Reva et al., 2011) implements a more elaborate conservation-based 
approach. It computes residue distribution entropy in multiple sequence alignments and 
estimates mutation impact by measuring the entropy difference caused by the mutation 
(conservation score). Moreover, the algorithm classifies protein alignment into distinct 
subfamilies with a clustering algorithm and quantifies the entropy difference initiated by a 
mutation in protein subfamilies (specificity score). The final “functional impact score” 
combines these two independent scores. 
1.1.2 Machine learning models 
PolyPhen2 (Adzhubei et al., 2010) integrates eight sequence and three structure-based 
attributes for the description of an amino acid substitution, and predicts the damaging effect of 
a coding mutation. Most PolyPhen2 features compare a property of the wild-type allele 
(ancestral, normal) and the corresponding property of the mutant allele (derived, disease-
causing) and characterizes how likely the two human alleles are to occupy the site given the 
pattern of amino-acid replacements in a multiple-sequence alignment. The probability of a 
deleterious allele replacement is predicted using a Naïve Bayes classifier trained on HumDiv 
and HumVar (Capriotti et al., 2006), two databases of damaging alleles. 
CHASM uses a random forest classifier to discriminate driver missense mutations from 
synthetically generated passenger mutations (Carter et al., 2009). It includes 49 predictive 
features ranging from exon conservation to UniProt annotation and frequency of the missense 
change type in the COSMIC database of cancer mutations (Forbes et al., 2011a). The program 
computes a classification score for each missense mutation. A mutation is determined to be 
driver or passenger by comparing its score to a null distribution made of scores from a filtered 
set of synthetic passengers that were held out from the Random Forest training. 
SNAP (Screening for Non-acceptable Polymorphisms) is a neural network-based tool that 
predicts the effect of a missense variant (Bromberg and Rost, 2007). It uses PMD (the Protein 
Mutant Database) (Sjöblom et al., 2006) and incorporates evolutionary constraints, transition 
frequencies for mutations, biophysical characteristics of the substitution, secondary structural 
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information, relative solvent accessibility, and SwissProt annotations information to build a 
neural network model, which is trained on known mutations from PMD. 
MutPred (Li et al., 2009) is another Random Forest classifier trained on five databases of 
human amino acid substitutions, CANCER (Sjöblom et al., 2006), KINASE (Greenman et al., 
2007), The Human Gene Mutation Database (HGMD)(Stenson et al., 2009), Swiss-
Prot (Boeckmann et al., 2003) and a broad array of attributes describing structure features 
(such as secondary structure, solvent accessibility), a variety of functional sites (such as 
DNA-binding or phosphorylation sites), evolutionary conservation and transition frequencies. 
The MutPred model then associates a given non-synonymous mutation to a probability of gain 
or loss of structural and functional features. 
1.1.3 Hybrid models 
The current trend for increasing the accuracy of impact measure is to integrate different 
methods. For example, CanPredict (Kaminker et al., 2007a) uses a random forest classifier to 
predict whether a change is likely to be cancer-associated, based on analyses of three scores: 
the SIFT score determining functional impact of change, the Pfam-based LogR.E-value 
metric (Clifford et al., 2004) and the Gene Ontology Similarity Score (GOSS), which 
measures how similar a given mutated gene is to known cancer-causing genes (Kaminker et 
al., 2007b). 
Condel (González-Pérez and López-Bigas, 2011) combines the output from PolyPhen2, SIFT, 
Mutation Assessor, Pfam-based LogR.E-values and MAPP (Stone and Sidow, 2005), which 
predicts deleterious mutations based on their disruption of physicochemical protein 
characteristics. Another hybrid tool, CoVEC (Consensus Variant Effect 
Classification) (Frousios et al., 2013) integrates prediction results from SIFT, PolyPhen2, 
Mutation Assessor and SNPs&GO (Calabrese et al., 2009), a scoring system based on 
functional protein features such as sequence conservation and GO-terms. Finally, Combined 
Annotation scoRing toOL (CAROL) combines the scores of PolyPhen-2 and SIFT to predict 
the effect of non-synonymous coding variants (Lopes et al., 2012). Expectedly, the authors of 
Condel, CoVEC and CAROL demonstrate that these tools outperform most individual 
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methods in classifying variants as damaging or neutral, highlighting the benefits of combined 
approaches (Frousios et al., 2013; González-Pérez and López-Bigas, 2011; Lopes et al., 2012). 
1.1.4 Comparing coding mutation scoring tools 
The authors of CoVEC (Frousios et al., 2013) assessed the classification performance of their 
tool and nine other prediction softwares: SIFT, PolyPhen2, SNPs&GO, PhD-SNP, 
PANTHER, Mutation Assessor, MutPred, Condel and CAROL. Based on the programs' 
ability to properly classify HGMD inherited disease-related variants (Stenson et al., 2009) and 
neutral SNPs, MutPred had the best performance in terms of true positive rate, followed by 
PolyPhen2. SNPs&GO showed most applicability in cases requiring minimal false positive 
rates. Most of the individual tools had similar overall (ROC curve-based) performances, 
however, combined tools such as CoVEC were shown to outperform the individual tools. In 
an independent benchmark, Thusberg et al (Thusberg et al., 2011) tested nine scoring tools for 
their ability to distinguish 40,000 pathogenic variants of the PhenCode database (Giardine et 
al., 2007) from neutral variants. Tested tools included MutPred, Panther, PhD-SNP, PolyPhen, 
PolyPhen2, SIFT, SNAP, SNPs&GO and nsSNPAnalyzer (Bao et al., 2005). Programs 
SNPs&GO and MutPred had best overall prediction accuracy. 
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Table 1. Summary of computational methods for predicting the effects of missense mutations 
in cancer. 
  
 Based on  Machine    
 learning  
Cancer-
specific  
Other tools 
used 
Web server, references 
SIFT 
 
Conservation 
   
Alignment  
scores  
No   http://sift.jcvi.org/(Ng and Henikoff, 2003) 
Polyphen 2 
 
Conservation  
Structure 
Training set 
Bayesian  
classification  
No   http://genetics.bwh.harvard.edu/pph2/)(Adzhubei et al., 2010) 
Mutation 
assessor 
Conservation  No  http://mutationassessor.org/(Reva et al., 2011) 
CHASM 
 
Conservation 
Structure 
Annotation 
Training set 
Random 
Forest  
Yes  http://wiki.chasmsoftware.org/index.php/MainPage(Carter et al., 2009) 
mCluster Training set  Yes  http://www.mcluster.org(Yue et al., 2010) 
SNAP 
 
Conservation 
Structure 
annotation 
Training set 
Neural 
network 
No Gene ontology http://rostlab.org/services/snap/(Bromberg and Rost, 2007) 
Canpredict   
 
Conservation 
Annotation 
Random 
forest 
Yes SIFT 
LogR.E 
GOSS 
http://research-public.gene.com/Research/genentech/canpredict/ 
(Kaminker et al., 2007a) 
MutPred 
 
Conservation 
Structure 
Annotation 
Training set 
Random 
forest 
No SIFT http://mutpred.mutdb.org/(Li et al., 2009) 
Condel Hybrid scoring system 
(weighted score) 
NA No PolyPhen2, 
SIFT, 
Mutation 
Assessor, 
Pfam-based 
LogR.E-values 
and MAPP 
http://bg.upf.edu/fannsdb/(González-Pérez and López-Bigas, 2011) 
CoVEC Hybrid scoring system SVM No SIFT, 
PolyPhen2, 
SNPs&GO, 
Mutation 
Assessor  
http://www.dcs.kcl.ac.uk/pg/frousiok/variants/index.html 
(Frousios et al., 2013) 
CAROL Hybrid scoring system No No SIFT, 
PolyPhen2 
http://www.sanger.ac.uk/resources/software/carol(Lopes et al., 2012) 
nsSNPAnalyzer structural and 
evolutionary 
information 
Random 
forest 
No  http://snpanalyzer.utmem.edu/(Bao et al., 2005) 
PANTHER 
 
Conservation 
 
Alignment  
scores  
No  http://www.pantherdb.org/tools/csnpScoreForm.jsp(Thomas et al., 2003) 
PhD-SNP 
 
Conservation 
Training set 
Support vector 
machine 
No  http://gpcr2.biocomp.unibo.it/cgi/predictors/PhD-SNP/PhD-SNP.cgi 
(Capriotti et al., 2006) 
SNPs&GO Conservation 
Swissprot features  
Support vector 
machine 
No  http://snps-and-go.biocomp.unibo.it/snps-and-go/(Calabrese et al., 2009) 
MAPP Physicochemical  
constraints 
NA No  http://mendel.stanford.edu/supplementarydata/stone_MAPP_2005/ 
 (Stone and Sidow, 2005) 
IntOGen-
mutations 
Hybrid scoring system NA Yes PolyPhen2, 
SIFT, 
Mutation 
Assessor 
http://www.intogen.org/web/mutations/v04/search 
(Gonzalez-Perez et al., 2013) 
16 
 
1.2 Integrating recurrence for driver prediction 
Further to prioritizing individual mutations as shown above, a variety of approaches predict 
driver genes by combining mutation scores and recurrence patterns. The assumption 
underlying these methods is that genes critical to the development of a specific cancer type 
should be recurrently mutated in a cohort of cancer samples. Several programs are available to 
identify such genes (Chapman et al., 2011; Ding et al., 2008; Gui et al., 2011;Wang et al., 
2011;X. Wei et al., 2011). 
IntOGen-mutations is a web server aiming to identify cancer drivers across tumor types 
(Gonzalez-Perez et al., 2013). The system first determines the consequences of mutations 
using the Ensembl variant effect predictor tool which offers a comprehensive database of 
variations, their effects and context (Chen et al., 2010) and uses three of the above tools (SIFT, 
PolyPhen2 and MutationAssessor) to compute the functional impact score of a somatic 
mutation. These functional scores are then transformed into a uniform score which measures 
the damaging impact of somatic mutations with transFIC (González-Pérez and López-Bigas, 
2011). This pipeline also computes each mutation's frequency of occurrence within and across 
cancer projects and groups mutations occurring in the same gene (or pathway). Subsequently, 
OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012) which detects genes accumulating 
mutations with high functional impact (FM bias) and OncodriveCLUST tools (Tamborero et 
al., 2013) which determine genes whose mutations cluster in particular regions of the protein 
sequence in comparison with synonymous mutations (CLUST bias) are used to identify 
positively selected genes, i.e. genes whose mutations are selected during tumor development 
and are therefore likely drivers. Finally, the pipeline computes the frequency of mutation of 
each gene (and pathway) within a cancer class (Figure1).  
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Figure1. Schematic display of the Oncodrive-fm driver detection tool (Gonzalez-Perez and Lopez-
Bigas, 2012). 
Oncodrive-fm is constructed based on the hypothesis that driver genes display the bias toward 
the enrichment of variants with high function impact (FI). (A) The first step of Oncodrive-fm 
is measurement of FI scores of coding variants detected in multiple cancer samples with SIFT, 
polyphen2 and MutationAssessor. (B) Secondly, Oncodrive-fm evaluates whether a gene 
possesses a shift toward the enrichment of variants with high FI, it compares the FI of 
observed variants to a null distribution and computes a P-value for each gene. RFM, 
Recurrent and FM biased; lRFM, Lowly Recurrent and FM biased; RnFM, Recurrent but not-
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FM biased. (C) Lastly, Oncodrive-fm can also detect gene modules or pathways that possess 
the FM bias. 
The MutSigCV method (Lawrence et al., 2013) assesses the background mutation rate for 
each gene–patient–category combination based on the observed silent mutations in the gene 
and non-coding mutations in the surrounding regions. It pools data from other genes with 
similar properties (for example replication time, expression level) to increase accuracy. 
Significance levels (P values) are determined by examining whether observed mutations in a 
gene significantly exceed the expected counts based on the background model (Figure2). 
Figure2. Overall concept of detection of recurrently mutated genes of MutSigCV in a cohort of 
cancer samples (Lawrence et al., 2013). 
MuSiC relies on the calculation of a background mutation rate (BMR) (Dees et al., 2012). The 
algorithm counts the number of bases with sufficient aligned read-depth based upon user-
defined coverage. Counts are determined for A, T, C and G as CpG dimers, and non-CpG C 
and G. Discovered mutations are categorized according to mutational mechanism, with 
separate categories for AT transitions, AT transversions, CpG transitions, CpG transversions, 
CG (non-CpG) transitions and transversions, and a seventh „indel‟ category. The BMR of 
each mutational mechanism category is calculated by dividing the number of mutations found 
in that category by the total number of bases available in which such a call could have been 
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made. Significantly mutated genes are generated by comparisons of mutation rates to BMR, 
using statistical tests. 
 
Figure 3. Identification of driver genes under positive selection with InVEx (Hodis et al., 2012) (A) 
Gene A possesses higher rate of nonsilent variants and silent/intronic variants in comparison with that 
of Gene B, indicating gene A is under positive selection of nonsilent variants in cancer.  (B) Schema 
of a random permutation-based approach to prioritize driver genes that possess positively selected 
nonsilent mutations with respect to a null distribution. 
InVEx is a random permutation-centered algorithm (Hodis et al., 2012) that relies on the 
assumption that a gene under positive selection for nonsilent mutations during cancer 
formation displays a higher rate of high-scoring non-synonymous mutations than silent and 
intronic mutations. A random permutation test is performed across each gene and a “mutation 
burden” score is calculated for each randomized instance, providing a null model of score 
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distribution. The actual mutation burden observed for a gene across all samples is then 
compared to this distribution and a P-value is computed, assessing whether the observed 
coding mutations and genes undergo positive selection (Figure3).  
Although genes that are mutated with high recurrence are easily recognized, some cancer 
drivers are mutated in a small fraction (e.g. <1%) of tumors (Wood et al., 2007). Thus, 
methods that can classify mutations as either drivers or passengers on the basis of data that is 
independent of mutation frequency clearly become important. There are many ways of 
combining mutation deleteriousness, recurrence and knowledge of mutational background. 
Computational options in this area are far from fully explored and we may thus expect 
improved driver predictors in the future. Furthermore, the application of these methods to the 
non-coding genome is a fascinating perspective, as so little is known about driver elements in 
these regions. This challenge may soon become accessible thanks to development of scoring 
systems for non-coding mutations, as explained in the next sections. 
1.3 Non-coding elements and cancer 
The list of non-coding elements involved in gene expression regulation has been steadily 
increasing over the years. Promoters, enhancers, splicing regulators and the expanding family 
of regulatory ncRNA (mainly miRNAs and lncRNAs) are central elements of the cell 
regulatory network. Their function in the control of gene expression is similar to that of many 
protein-coding cancer drivers, half of which are involved in transcriptional and 
posttranscriptional regulation. Therefore, it comes as no surprise that mutations within these 
non-coding elements are responsible for the initiation and progression of cancer, among other 
diseases (Andersson et al., 2014; F. W. Huang et al., 2013; Khurana et al., 2013; Killela et al., 
2013; Horn et al., 2013). 
The first non-coding cancer hotspots to be suspected were promoters and TF binding sites. 
Indeed, among 4,492 phenotype-associated SNPs from the GWAS Central Database (Beck et 
al., 2014), 12% are located in binding regions of transcription factors, which is significant as 
these loosely defined regions represent 8.1% of the genome (Sato et al., 2013). Genetic 
variations at TF binding sites, including single-nucleotide polymorphisms and larger 
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structural variants, are frequently associated with binding affinity (Kasowski et al., 2010; 
Mcdaniell et al., 2010; Zheng et al., 2010), gene expression (Sugimachi et al., 2014; French 
and Et Al, 2013) and cancer susceptibility, progression and outcome (Jiang et al., 2012; Lin et 
al., 2014; S.-P. Huang et al., 2013). A well-known such locus is the TERT promoter, whose 
mutations were established as drivers in melanomas and gliomas (Killela et al., 2013; F. W. 
Huang et al., 2013; Horn et al., 2013). 
Another important class of regulatory element is that of splicing regulators. Misregulation of 
RNA splicing initiated by genetic variants is a cause of human disease, including cancer. 
Alteration of 5'and 3' splicing sites and adjacent bases accounts for 10% of human inherited 
disease mutations (Sterne-Weiler and Sanford, 2014; Krawczak et al., 2007) and the number 
of tumor-relevant splicing variants detected by GWAS in cancers reaches 15,000 (He et al., 
2009; Venables et al., 2008; Shapiro et al., 2011). For example, a germline mutation in the 
splicing site of hSNF5 is causative of exon 7 skipping and subsequent frameshift, which, as a 
result, renders infants susceptible to develop malignant brain tumors (Taylor et al., 2000). 
Likewise, a mutation at the acceptor site of the APC gene intron 3–exon 4 junction causes the 
loss of exon 4, which accordingly terminates seven codons downstream of junction 4, a 
phenomenon closely associated to childhood hepatoblastoma (Kurahashi et al., 1995). 
Variation in non-coding RNA (ncRNA) sequence and expression is another potential 
component of cancer progression. The first important offenders in this class were miRNAs. 
Single nucleotide variations in miRNA sequences or in their mRNA target sites lead to 
alteration of binding specificity, thus affecting expression and/or translation of target 
mRNAs (Manikandan et al., 2012; Gopalakrishnan et al., 2014; Kamaraj et al., 2014; 
Manikandan and Munirajan, 2014; Vaishnavi et al., 2014). For instance, SNPs in mRNAs of 
the CEP family of cell division genes, alter mRNA/miRNA interactions, greatly affecting 
mRNA expression, disrupting the cell cycle and contributing to initiate cancer(Kamaraj et al., 
2014)  Overall, more than 236 miRNAs have been associated to 79 human cancers either as 
potential oncogenes or tumor suppressors (Xie et al., 2013). 
Long non-coding RNA is the most recent class of regulatory ncRNA to be associated to 
cancer. According to a recent study (Iyer et al., 2015), over 68% (58,648) of expressed genes 
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in human tumors are lncRNAs, 7942 of them lineage- or cancer-specific. Through gene 
regulation or other mechanisms, lncRNAs may act as proto-oncogenes, tumor suppressor 
genes or drivers of metastatic transformation. For instance, the HOTAIR lncRNA is highly 
expressed in primary breast tumors and metastases, as well as in gastric cancer, and its 
repression inhibits xenograft tumor growth and metastasis in mouse models (Gupta et al., 
2010; Okugawa et al., 2014). MALAT1 is another lncRNA whose expression is correlated 
with metastasis and survival in lung cancer (Ji et al., 2003). Knockout of MALAT1 greatly 
impairs the migration and formation of tumor nodules of MALAT1-deficient A549 cells in a 
mouse xenograft (Gutschner et al., 2013). Jin et al. (Jin et al., 2011) observed that among a set 
of 33 SNPs independently associated with elevated prostate cancer (PCa) risk, eight were 
located in lncRNAs. Moreover, lncRNA loci showed a five-fold enrichment of PCa risk-
related SNPs in comparison with the entire genome. SNPs in the lncRNA PRNCR1 were 
proposed to be related to colorectal cancer (CRC) risk (L. Li et al., 2013). 
In spite of these recent advances, the list of cancer-driving elements in the non-coding 
genome remains extremely short with respect to the size of the regions involved. A major 
avenue in identifying new potentially relevant loci involves exploring chromatin states. 
Indeed, regions where chromatin is open or active in a given cell type are the most likely to 
contain key regulatory elements. For instance, DNase I hypersensitive sites (DHSs),i.e. DNA 
regions sensitive to the DNase I enzyme, harbor many regulatory elements such as enhancers, 
promoters and silencers (Gross and Garrard, 1988; He et al., 2014). Moreover, DHSs are 
associated with elevated levels of nearby gene expression, at least in certain cells (He et al., 
2014). Other important functional hallmarks are provided by histone modifications such as 
acetylation and methylation, which control chromatin states and are thus important regulators 
of gene expression (Dawson and Kouzarides, 2012). Specific histone marks suggest different 
types of regulatory elements: H3K4me3 generally marks promoters and transcription start 
sites. Putative enhancers tend to be marked with H3K4me1 alone or in combination with 
H3K27ac or H3K27me3 (Rada-Iglesias et al., 2011; Zentner et al., 2011). Conversely, major 
repressive marks, such as H3K9me3 and H3K27me3, are associated with constitutive 
heterochromatin and repetitive elements, repressive domains and silent developmental 
genes (Rada-Iglesias et al., 2011) and are therefore less likely to harbor cancer drivers. 
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1.4 Prioritizing non-coding variants 
Although the number of cancer-associated non-coding mutations is increasing, finding cancer-
driving mutations in the non-coding genome remains a huge challenge. A major bottleneck 
lies in identifying functional domains while trying to explore the consequences of the 
variations. Functional interpretation of non-coding variations is now turning into a realistic 
goal through the completion of major high-throughput studies such as the Encyclopedia of 
DNA Elements (ENCODE) (Rosenbloom et al., 2013), the “29 Mammals” Project (Lowe and 
Haussler, 2012), the Health Roadmap Epigenomics project (Bernstein et al., 2010) and other 
large scale regulatory data collections (Rhee and Pugh, 2011; Yu et al., 2011; Zeller et al., 
2010)(Degner et al., 2012; Palii et al., 2011). Particularly, The ENCODE Project has provided 
researchers with genome-wide mapping of histone modification, Dnase I hypersensitive sites, 
FAIRE sites (formaldehyde-detected nucleosome-depleted elements), transcription factor 
binding sites, RNA-seq expression data and replication timing across multiple cell 
lines (Rosenbloom et al., 2013). These extensive data form a major stepping-stone toward the 
functional annotation of non-coding variants. More and more studies are taking advantage of 
these annotations to explore and prioritize non-coding variants implicated in cancer and other 
diseases. Table 2 presents seven systems that are currently available for scoring non-coding 
variants. We distinguish below two families of such methods, based either on empirical 
scoring systems or on machine learning. 
1.4.1 Empirical scoring systems 
The RegulomeDB database and software (Boyle et al., 2012) assigns functions to non-coding 
variants based on the principle that a variant impacting a regulatory element likely results in 
functional consequence. Non-coding variants are classified into different functional categories 
according to their overlap with functional elements such as transcription factor binding, 
histone modifications, DNase I hypersensitive sites, FAIRE sites and eQTLs (expression 
Quantitative Trait Loci, that is loci likely to affect expression of target genes). Application of 
this tool to the annotation of non-coding variants from 69 full sequenced genomes (Clarke et 
al., 2012) identified thousands of potential functional variants. 
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The FunSeq tool (Khurana et al., 2013) predicts non-coding drivers by scoring the deleterious 
potential of variants, based on two assumptions. First, somatic variants in non-coding 
elements containing a high fraction of rare variants (derived allele frequency < 0.5%) are 
considered as under negative selection and thus are most likely to be cancer drivers. Second, 
driver mutations should be recurrent in the same genomic element across multiple cancer 
samples. Application of this workflow to 90 cancer genomes yielded nearly a hundred non-
coding drivers candidates. An improved algorithm, FunSeq2 (Fu et al., 2014) exploits large-
scale genome data from 1000 Genomes and ENCODE into a scoring pipeline that combines 
functional features such as sequence conservation, transcription-factor binding sites, 
enhancer-gene linkages, network centrality and recurrence across samples. In this model, 
features are weighted by their probability of overlapping a natural polymorphism in the 1000 
Genome database, which is a negative indicator of selection strength. Application of FunSeq2 
to germline pathogenic regulatory variants successfully distinguished HGMD (Human Gene 
Mutation Database) and GWAS non-coding pathogenic variants from neutral ones. The 
method also effectively scored COSMIC recurrent variants higher than non-recurrent variants. 
1.4.2 Machine-learning models 
While the RegulomeDB and FunSeq systems prioritize functional genetic variations using 
empirical models, recent methods aim to integrate functionally predictive features 
automatically using machine learning (Kircher et al., 2014; Ritchie et al., 2014; Shihab et al., 
2015). One of these models, GWAVA (Ritchie et al., 2014) uses regulatory mutations 
annotated in the HGMD database as a training set for non-coding variants of medical 
importance. These variants are predicted using a random forest classifier based on a 
combination of regulatory features, genic context and genome-wide properties such as DNase 
I hypersensitivity sites, FAIRE sites, Transcription factor binding sites, Histone modifications, 
RNA polymerase binding sites, complex epigenetic states, CpG islands, sequence 
conservation, allele frequency of variants and gene annotation. The model was able to 
effectively discriminate a set of disease-relevant variations of the ClinVar (Landrum et al., 
2014) and GWAS Central databases from control variants. More importantly, recurrent cancer 
mutations from the COSMIC database were scored significantly higher than non-recurrent 
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mutations, suggesting that this approach might be useful in prioritizing cancer driver 
mutations. 
Another tool, FATHMM-MKL, implements multiple kernel learning to weight different 
ENCODE feature annotations based on their relevance. The program builds a Support Vector 
Machine classifier based on a positive training set of non-coding pathogenic variants 
annotated in HGMD and a negative set of common single-nucleotide variants with allele 
frequency above 1% within 1-Kb surrounding disease-causing variants. The model uses for 
prediction a kernel matrix of 10 annotation features, including transcription factor binding 
sites, evolutionary conservation, DNase I hypersensitive sites and histone 
modifications (Shihab et al., 2015). A possible limitation in GWAVA and FATHMM-MKL is 
the methods highly rely on a set of promoter proximal, pathogenic mutations that are well 
characterized and thus are subject to ascertainment bias. 
Instead of building a classifier using limited curated pathogenic variants, the CADD 
system (Kircher et al., 2014) contrasts the annotations of fixed derived alleles in humans with 
those of de novo simulated variants. Here fixed (or nearly fixed) alleles are used as models for 
deleterious variants. The CADD system is trained to recognize such variants using a support 
vector machine classifier based on a combination of 63 tracks of annotations, including 
conservation, regulatory information, transcript information, protein-level score produced by 
SIFT, Polyphen or Grantham (Grantham, 1974). CAAD successfully differentiated 14.7 
million high-frequency human-derived alleles (observed variants) from 14.7 million simulated 
variants (half simulated de novo mutations). 
To conclude this section, we mention SPANR (splicing-based analysis of variants) (Hs et al., 
2015), a program that combines a Bayesian machine learning algorithm and a regulatory 
model of gene splicing to detect and score disease-associated genetic variants. The RNA 
splicing model integrates regulatory elements and splicing levels generated from RNA-seq 
data of healthy human tissues. SPANR is capable of a precise classification of both intronic 
disease-related variants and deleterious disease mutations within exons, from common 
variants in the dbSNP database. Analyses using SPANR have generated a large body of 
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splice-disruptive mutations involved in Autism, familial colorectal cancer and spinal muscular 
atrophy, which are known for RNA-splicing deregulation. 
1.4.3 Comparing non-coding variant scoring tools 
To illustrate the divergence of predictions by different non-coding mutation scoring systems, 
we selected seven tools from the current literature (CAAD, FunSeq, FunSeq2, GWAVA, 
RegulomeDB, Fathmm-MKL and SPANR) and used them to score 874,325 non-coding 
variants (both substitutions and short indels) from the whole genome sequencing of 88 liver 
cancer samples (Lawrence et al., 2013). First, we should note that all tools are not applicable 
to the entire set of somatic mutation (Fig. 4A). GWAVA, RegulomeDB, and funSeq2 were 
able to score over 99% of variants, while SPANR provided scores for only 2.48% of variants 
due to its specificity for splicing regulation. Due to this different scope, we excluded SPANR 
from further comparison. We scored the 841,402 somatic mutations covered by the other 5 
tools and collected the 10,000 highest scoring variants from each tool. The Venn diagram 
in Fig. 4B shows the overlapping of predictions. Strikingly, even though there is a higher 
overlap of highest scoring variants among five tools as compared to 10000 randomly sampled 
ones (P value=0, a permutation test), only 13 variants are commonly predicted as high scoring 
by all five tools, illustrating the remarkable divergence of non-coding variant prioritization 
strategies. While a full benchmark of the different prediction algorithms is beyond the scope 
of this review, we may refer to two studies that assessed the performances of various non-
coding variant prioritization tools in classifying sets of known deleterious HGMD variants. 
Each study compared a specific program developed by the authors to leading “state-of-the-art” 
algorithms. Fu et al. (Fu et al., 2014) showed that FunSeq2 has a better average prediction 
power compared to GWAVA and CAAD, while Shihab et al. (Shihab et al., 2015) showed 
that FATHMM-MKL outperformed GWAVA and CAAD in terms of accuracy. Due to the 
substantial number of recently developed methods, a full scale and independent comparative 
study would be valuable to provide consistent results and objectively identify the strengths 
and weakness of each tool. 
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Figure 4. Comparison of six non-coding mutation scoring tools. A. Fraction of positions covered by 
each tool in a set of 874,325 non-coding variants. B. Overlap of the 10,000 top-scoring variants, using 
the 5 scoring tools with the larger prediction coverage (CADD, Fathmm-MKL, FunSeq2, GWAVA 
and RegulomeDB), from the 841,402 variants common to their prediction coverage. Five set of 10000 
variants were randomly sampled from the 841,402 variants covered by five tools, the overlap was 
calculated accordingly. The sampling process was repeated 1000 times, the significance of overlap of 
10000 high scoring variants was compared to the 1000 overlaps of random sampling variants.  
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Table 2. Summary of computational approaches for predicting the damaging effects of non- 
coding mutations  
 
 Based on  Machine    
 learning  
Cancer-
specific  
Web server, references 
Regulome
DB 
 
Overlap with functional 
elements 
Empirical 
Scoring 
systems 
No  http://www.regulomedb.org/(Boyl
e et al., 2012) 
Funseq 
 
Negative selection in 
general population 
recurrent cancer 
mutations 
Empirical 
Scoring 
systems 
Yes http://funseq.gersteinlab.org/ (Khu
rana et al., 2013)  
Funseq2 Negative selection in 
general population 
recurrence   in cancer 
mutations 
Empirical 
Scoring 
systems 
Yes http://funseq2.gersteinlab.org/ (Fu 
et al., 2014)  
GWAVA 
 
HGMD regulatory 
mutations, integrated 
genome annotation 
Random 
Forest  
No https://www.sanger.ac.uk/sanger/S
tatGen_Gwava(Ritchie et al., 
2014) 
CADD Deleteriousness,diverse 
genome annotation 
support 
vector 
machine 
No http://cadd.gs.washington.edu/ (Ki
rcher et al., 2014) 
SPANR RNA splicing model Bayesian 
machine 
learning 
No http://tools.genes.toronto.edu/(Hs 
et al., 2015) 
FATHMM
-MKL 
HGMD mutations, ten 
feature annotations (6 
from ENCODE) 
support 
vector 
machine 
No http://fathmm.biocompute.org.uk(
Shihab et al., 2015) 
 
 
1.5 Conclusion 
The search for cancer drivers requires a reliable functional annotation of variants and adapted 
tools for analyzing the recurrence of deleterious variants across patients. The former requisite 
is particularly challenging in the non-coding genome. An active research community is 
developing tools for non-coding variant annotation and prioritization using a variety of 
methods ranging from empirical scoring scheme to machine-learning and elaborate hybrid 
frameworks. Due to the heterogeneity and complexities of these scoring tools, objective 
comparisons based on proper benchmarks using different sets of validated or probable 
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disease-causing variants are strongly required. Among multiple sources of possible 
improvement, the success of hybrid methods for scoring coding variants, and the widely 
divergent predictions by the non-coding tools suggest that combining outputs from different 
tools will significantly increase scoring accuracy for non-coding variants. A further challenge 
is to jointly consider this “functional” score and the heterogeneity of cancer specific mutation 
constraints in different genome areas. These potential enhancements suggest we can expect 
important reliability gains in non-coding variant prioritization in the near future. 
 
As described above, there are a handful of computational tools used to evaluate the functional 
impact of non-coding mutations. However, certain limitations still exist for these prediction 
tools. For example, empirical scoring systems, such as RegulomeDB and funSeq2, cannot 
provide a precise measure of functional information for non-coding variants, while machine 
learning models, such as FATHMM-MKL and GWAVA, might be overfitted to a small set of 
HGMD disease mutations and show major ascertainment biases, and CADD doesn‟t take into 
account cancer mutation information in its scoring system. Moreover, although an increasing 
number of cancer-associated lncRNAs has been experimentally characterized, an efficient 
computational tool to prioritize cancer-driving lncRNAs is still missing, mainly owing to the 
sophisticated and diverse mechanisms by which lncRNAs act. Therefore, it becomes 
increasingly urgent and important to develop a scoring system that accurately measures the 
functional effect of non-coding cancer mutations and then injects this functional information 
into a computational program for the detection of non-coding drivers.   
In the following studies, we hypothesized that purifying selection as measured by the fraction 
of rare SNPs in general population and mutation density (number of mutations /Mb) 
constraint are two important measures of functional impact of cancer mutations in the non-
coding cancer genome. In order to functionally score non-coding mutations in cancer and 
eventually identify new cancer drivers, we took into account the dual selection forces acting 
on the tumor genome: (1) population and evolutionary constraints acting at germline level and 
(2) constraints resulting from the accelerated mutation background of the cancer tissue. To 
achieve this, we have developed two independent random forest models, referred to as SNP 
and SOM models. The SNP model predicts expected fraction of rare SNPs for any non-coding 
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region based on a combination of features, the SOM model computes the expected mutation 
density for each 1-Mb window with an array of feature types ranging from replication time, 
expression level, histone modifications to regulatory elements. The two models are capable of 
discriminating disease-associated variants from Clivariant and HGMD databases from a set of 
random control SNPs, strongly supporting our hypothesis. This study is the object of the 
following chapter.   
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Chapter 2 – Non-
coding driver 
mutations 
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A dual model for prioritizing cancer mutations in the non-coding genome based on 
germline and somatic events 
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Comput Biol. 2015. 11(11):e1004583. 
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2.1 Summary 
 
Cancer cells undergo a mutation/selection process that resembles that of any living cell. Most 
mutations in cancer cell DNA occur in the so-called "non-coding" regions that represent 98.5% 
of the genome length. Pinning down which of these mutations contribute to the fitness of 
cancer cells would be important for identifying new "cancer drivers", which may in turn lead 
to future treatments. Unfortunately, predicting the impact of a non-coding DNA alteration 
remains extremely difficult. In this study, we analyze millions of non-coding cancer mutations 
and show cancer-specific mutational patterns can be used to predict non-coding regions that 
are preserved from mutations and may thus be important for cancer cell survival. Combining 
this information with population data, we propose a new scoring system that should help 
prioritize important non-coding mutations in future studies.  
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2.2 Introduction 
Since the onset of cancer genomics, the search for cancer genes and cancer-causing mutations 
has largely focused on protein-coding genes and, more specifically, their coding exons, where 
the damaging effect of mutations is best understood. Among 572 human genes considered as 
cancer drivers (Futreal et al., 2004; D‟Antonio and Ciccarelli, 2013), nearly all are protein-
coding. However protein-coding regions only represent a tiny subset of the vast transcribed 
area composed of over 50,000 non-coding genes (Harrow et al., 2012; Iyer et al., 2015) and 
the introns and untranslated regions (UTRs) of mRNA genes. Even though a large part of the 
non-coding transcribed regions is probably non functional (Ulitsky and Bartel, 2013), 
analyses based on evolutionary conservation or allele frequencies in human populations 
(Ponting and Hardison, 2011; Ward and Kellis, 2012) estimate that 10 to 15% of the overall 
genome is under selection, that is 7-10 times larger than protein-coding regions.   
Non-coding mutations may cause damaging effects in many distinct ways. They may alter 
RNA structure (Corley et al., 2015) or binding sites for proteins or other RNAs, such as 
splicing sites (Jolly et al., 1994) and microRNA target sites in 3‟ UTRs, or impact regulatory 
sequences in gene promoters and enhancers. A recent population genomics study estimates 
that there are in average 15 highly deleterious mutations in the non-coding DNA of any 
healthy individual (Khurana et al., 2013). This large source of potentially damaging mutation 
remains mostly untouched by cancer genomics. In-depth analysis of the mutational load in the 
non-coding fraction of the genome is needed for the comprehensive understanding of cancer 
progression, as well as for the identification of new cancer drivers and therapeutic targets.  
Whole genome normal vs. tumor sequencing commonly reveals thousands to tens of 
thousands of somatic mutations (Alexandrov et al., 2013; Kandoth et al., 2013; Lawrence et 
al., 2013), scattered across all genomic areas. In coding regions the genetic code and 
aminoacid conservation rules provide a robust functional model for scoring mutational 
damage (Adzhubei et al., 2010; Ng and Henikoff, 2003). Similarly reliable tools are needed 
for non-coding regions in order to prioritize non-coding mutations and seek gene regions 
acquiring deleterious mutations at an unusual pace across a set of tumor samples. Several 
scoring systems for non-coding mutations already exist. The RegulomeDB system (Boyle et 
al., 2012) scores variants using an empirical metric based on their overlap with transcription 
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factor (TF) motifs, known TF binding site, chromatin marks or expression QTLs (eQTL) and 
thus is clearly centered on regulatory DNA variants. Other scoring models consider allele 
frequencies in human populations. Rare alleles are more often associated to reduced or lost 
gene activity than frequent alleles (Urban, 2005) and a high local ratio of rare to total SNP is 
indicative of purifying selection (Khurana et al., 2013; Chen and Rajewsky, 2006; Lomelin et 
al., 2010; Haerty and Ponting, 2013). Khurana et al. used SNP data from the 1000 Genome 
project (Clarke et al., 2012) to identify about 0,4% of the genome (12Mb) as sensitive to 
mutations and introduced an empirical scoring system (Funseq) to rate somatic mutations 
based on their presence in sensitive segments and overlap with known regulatory elements 
(Khurana et al., 2013; Fu et al., 2014). Likewise, the CADD system (Kircher et al., 2014) 
predicts the deleteriousness of non-coding mutations based on allele frequencies modeled 
using machine learning on a series of genome features. Recently, Ritchie et al. introduced a 
model for prioritizing non-coding variants based on databases of known disease-related 
mutations (Ritchie et al., 2014). The authors used machine learning to predict regions where 
disease-causing variants are most likely, using as explanatory variables functional features 
such as exon annotations, histone and other chromatin marks or transcription factor binding 
sites (TFBS). However useful, these models have limitations in that they are often directed 
towards the detection of regulatory elements (where 75% of disease variants have been 
located to date (Ritchie et al., 2014) and they only consider human mutations in the light of 
germline, evolutionary selection, meaning independently of a specific tissue or disease 
context. This latter point is especially important in cancer, where (1) most disease-inducing 
mutations occur somatically during the lifetime of an individual, and (2) these mutations may 
have different impacts when occurring in different tissues. 
The availability of multiple whole genome sequence (WGS) data from tumors and matched 
normal tissue has revealed the extensiveness and singularity of cancer somatic mutations 
(Alexandrov et al., 2013; Kandoth et al., 2013; Lawrence et al., 2013). Cancer cells divide 
under their own set of selective constraints by which large regions of the genome can sustain 
high mutation rates while others seem relatively protected. This accelerated mutation rate is 
an important factor that may cause recurrent mutations in genome areas that are not 
necessarily related to cancer. Methods for scoring putative driver mutations now take such 
35 
 
effect into account (Lawrence et al., 2013). 
Variation of the somatic mutation rates in different genome areas is by itself a rich source of 
functional information. Schuster-Böckler & Lehner (Schuster-Böckler and Lehner, 2012) 
related 45 functional features (mostly histone marks) to somatic mutation rates and observed 
that the major factor influencing mutation density was chromatin organization, marks of open 
chromatin being associated to a reduced SNV densities and marks of closed chromatin to 
higher densities. Cancer somatic mutations do not all cause cell death or tumor progression, 
but they may contribute to tumor heterogeneity which in turn facilitates the emergence of new 
clones capable of surviving micro-environmental changes and drug treatments (Podlaha et al., 
2012). In this sense, the somatic mutation landscape can be considered as a model of 
accelerated evolution in which most mutations are neutral and a handful is under selection as 
beneficial to tumor progression.  
A strong hypothesis guiding the present study is that, in order to prioritize non-coding 
mutations in cancer and eventually discover new cancer drivers, one should take into account 
these dual selection forces acting on the tumor genome: (1) population and evolutionary 
constraints acting at germline level and (2) constraints resulting from the accelerated mutation 
background of the cancer tissue. To this aim we developed two integrative models that use 
annotated genome features to predict germline or somatic mutation constraints at any genomic 
location. We compared the functional features that most influence each mutational regimen 
and analyzed the intersection of constrained regions predicted under each model. A new 
picture of the somatic mutational landscape emerges where regions under constraint in the 
germline may be subject to highly variable mutation rates in the tumor. We present evidence 
that low somatic mutation areas are functionally relevant and can be used as a powerful screen 
for prioritizing cancer-related non-coding mutations. 
 
2.3 Results 
We represent germline and somatic constraints acting on tumor genomes using two 
independent models, one for each mutational regimen, that we term the SNP model and the 
SOM model. For each model, we define a set of genome features, mainly from 
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UCSC/Ensembl genome annotation (Karolchik et al., 2014) and the ENCODE Project 
(Rosenbloom et al., 2013) and we use these features to predict the expected mutational 
constraint at any genome position. In the SNP model, the mutational constraint is expressed as 
a regional ratio of rare SNP, while in the SOM model it is expressed as a regional mutation 
density. We further describe each model below.  
2.3.1 Scoring mutations with the germline (SNP) model 
A high regional ratio of rare SNPs (i.e. SNPs with allele frequencies below 0.5 or 1%) is a 
hallmark of genome regions under negative / purifying selection (Chen and Rajewsky, 2006; 
Khurana et al., 2013; Haerty and Ponting, 2013). Figure 1A shows varying ratios of rare SNPs 
obtained from the 1000 Genome Project (Clarke et al., 2012) associated to known functional 
regions or "features"' (see Table S1 for each feature definition). Coding regions (CDS) clearly 
stand out as more constrained than non-coding regions in general. However, a number of non-
coding elements also depart from the average genome signal, reflecting prior analysis of the 
1000 Genome project data (Khurana et al., 2013). Regions under purifying selection (ie. with 
high rare SNP ratio) include evolutionary conserved regions, transcription factor binding sites, 
DNase I hypersensitive, early replicated and highly expressed regions. Inversely, we observed 
low ratios of rare SNPs in regions of strong GC-bias, high replication rate and evolutionary 
conserved RNA structures (ECS). Of note, this low ratio of rare SNP in ECS is in 
disagreement with the expected deleterious effect of mutations in functional RNA structures. 
We developed a Random Forest (RF) model to predict purifying selection at any genome 
position based on the features present at this position. To this aim we associated every non-
coding genome position to a vector of binary values describing the presence/absence of 
functional features at this location (see Table S1 and Methods). Following feature selection 
and cross-validation, we obtained a robust model associating any combination of 16 genomic 
variables to a predicted rare SNP ratio. A measure of importance of each feature's 
contribution to the RF model is shown in Fig.1B. Evolutionary conserved regions, promoters 
and conserved transcription factor binding sites are among the strongest contributors to rare 
SNP ratio, in line with previous studies (Clarke et al., 2012). Of note, the predictive value of a 
high recombination rate, which is associated to a low rare SNP ratio (Fig 5A), had not been 
reported before. 
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To evaluate how the SNP model alone can predict deleterious mutation in the non-coding 
genome, we compared the average scoring of one million random SNPs to that of non-coding 
variants from two distinct collections of disease-related mutations, the Clivariant (Landrum et 
al., 2014) and HGMD (Stenson et al., 2009) databases (Fig. 5C). Known clinical variants 
from either database have significantly higher scores by the SNP model than random variants 
(Wilcoxon P<2.2e-16 in both cases). Furthermore, scores in the SNP model are positively 
correlated to the density of disease-related SNPs (Fig 5D, r= 0.80 and 0.73, P=6.09e-08 and 
3.15e-06 for Clivariant and HGMD, respectively), which confirms the capacity of the SNP 
model to identify non-coding regions where mutations are more likely to be disease-related.  
 
Figure 5. Construction of the rare SNP model.  A. Fraction of rare SNPs (allele frequency <0.01) 
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according to different genome features (see Table S1 and Methods for feature details). Each box 
shows rare SNP fraction across all human chromosomes, except chr. Y.  CDS: coding sequence; 
cTFBS: conserved transcription factor binding site; CR: evolutionary conserved region; UTR: 
untranslated region; Sensitive: region with high rate of rare SNP defined in (Khurana et al., 2013), 
ER/LR: early and late replicated region; DNase: DNase I hypersensitive site; HE/LE: high and low 
expressed region; Intron L/Intron P: intron of lncRNA/of protein coding gene; ncExon: non coding 
exon; ECS: evolutionarily conserved structure; RR H/RR L/GC H/GC L: high recombination rate, low 
recombination rate, high GC content and low GC content regions. The red dotted line represents the 
average fraction of rare SNPs across the genome. B. Feature importance as measured by 
IncNodePurity. We only show here features that passed feature selection. C. Distribution of SNP 
scores for random SNPs and for clinical variants from the Clivariants and HGMD databases. Random 
SNPs here are a set of 1M random intergenic SNPs from the 1000 Genome project. D. Correlation of 
SNP scores with densities of disease-causing variants. Genome positions were sorted by SNP score 
and split into 20 Mb intervals. The plots show the average SNP score and density of disease-causing 
variants for each interval. The purple dotted line shows cutoff used for defining high SNP score 
thereafter.  
2.3.2 Scoring mutations with the somatic (SOM) model 
The tumor mutational landscape results from the combined action of multiple factors 
including mutagenic agents, accelerated cell division, impairment of DNA replication/repair 
pathways and resistance to treatment (Lawrence et al., 2013). The tumor genome is thus 
subject to a set of constraints that are quite distinct from those acting in the germline. To 
analyze these constraints, we collected somatic mutation data from whole genome sequencing 
of liver cancer (N=88 patients), chronic lymphocytic leukemia (CLL) (N=28), lung 
adenocarcinoma (N=24) (Alexandrov et al., 2013) and melanoma (N=25) (Berger et al., 2012). 
We analyzed mutation densities for the above genomic features and for tissue-specific 
features such as histone marks, early/late replicated regions and transcript abundance obtained 
from tissue-matched Encode cell lines  (Rosenbloom et al., 2013) (Table S2). Results are 
shown in Figure 6A, S1A, S2A, S3A. Protein-coding sequences (CDS) harbor relatively low 
somatic mutation densities compared to introns (intron.P) and intergenic regions in all four 
cancer types, consistent with higher functional constraints in CDS, as observed in the SNP 
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model. However, other features reveal a quite different pattern. Evolutionary conserved 
regions, cTFBS and UTRs that were all under strong selective constraints in the germline 
model present highly variable mutation densities in tumors, with densities ranging from low 
(CDS level) to high (intergenic level), and no consistent pattern from tumor to tumor (Fig 6A, 
S1A, S2A, S3A). Certain features, however, present marked and consistent mutational 
patterns across all four tumors. For instance, we observed an obvious trend for accelerated 
mutation rates (higher density) in regions of repressed chromatin marks (H3K9me3), late 
replication (PCgene.late, lncRNA.late), low transcript expression (PCgene.LE, lncRNA.LE) 
and low GC (GC L). Conversely, we observed consistently reduced mutation rates in regions 
of active chromatin marks (H3K4me1-2-3, H3K79me2, H4K20me1), early replication 
(PCgene.early, lncRNA.early), high transcript expression (PCgene.HE, lncRNA.HE) and high 
GC (GC H). The general trends in feature-wise mutation densities largely reflect prior 
findings based on smaller datasets. Schuster-Bockler and Lehner (Schuster-Böckler and 
Lehner, 2012) observed strong correlations between chromatin states and mutation densities 
in tumors, with repressive marks linked to higher mutation rates, possibly due to deficient 
DNA repair in these regions. Mutation density is also known to correlate positively with late 
replication (Hodgkinson et al., 2012; Lawrence et al., 2013; Woo and Li, 2012) and 
negatively with recombination rate (Schuster-Böckler and Lehner, 2012) and RNA expression 
level (Lawrence et al., 2013; Pleasance et al., 2010).  
To model the mutational constraints acting on the tumor genome, we developed a second RF 
model, referred to as the SOM model, which predicts somatic mutation densities (the response 
variable) at any genome position based on the presence of cell-specific and generic genome 
features. We built one SOM model for each of the four above cancer types. Due to the large 
number of features in the SOM model and limited number of somatic mutations in the training 
sets, we computed feature coverage or average values (see methods) on successive 1Mb 
regions and trained the RF model based on the resulting vectors. After feature selection and 
robustness testing by cross-validation, the SOM model enabled reliable prediction of somatic 
mutation density at any genome location for each cancer type (see Methods). Fig 6B, S1B, 
S2B, S3B show the importance of features in the SOM models.  
RNA expression levels turned out to be relatively weak predictors of mutation density, 
40 
 
whereas replication time and histone marks in general are the predominant features 
determining somatic mutation density in all cancer types. However we observe significant 
differences between cancers. For instance the H3K36Me3 mark is an important predictor of 
low mutation density in melanoma and lung cancer, not in CLL or liver cancer. Also, CTCF 
binding sites are strong predictors of low mutation density in CLL and not in other cancer. 
Altogether this indicates that each somatic model predicts a cancer-specific mutation profile 
with distinct regions of high and low mutation densities.  
Under a neutral evolutionary model, somatic mutations should freely accumulate in regions 
that do not impact tumor fitness, thus regions of elevated tumor densities (high SOM score) 
should be considered as generally irrelevant to fitness, while regions that are relatively 
preserved from somatic mutations (low SOM score) are potentially the most interesting as 
they could reveal purifying selection occurring at the tumor level. One way to test this 
hypothesis is to relate low mutation regions and the occurrence of known disease mutations. 
Fig 6C, S1C, S2C, S3C show that non-coding disease mutations from the Clivariant and 
HGMD databases have significantly lower SOM scores than evolutionarily neutral SNPs 
(Wilcoxon P<2.2e-16 in all cases). Furthermore, the SOM score of different genome regions 
is inversely correlated to the density of disease causing variants in these regions (Fig 6D, S1D, 
S2D, S3D) (r =-0.47 to -0.94, P= 0.01 to 8.61e-14) suggesting that genome regions spared 
from somatic mutations are functionally relevant to disease progression.  
To further assess the value of SOM score as an indicator of selection, we mapped the genome 
positions with lowest SOM scores onto the different genome features and measured the 
relative enrichment for low SOM score positions within each feature (Fig. S4A). Expectedly, 
features that were part of the SOM model are significantly enriched or depleted in low SOM 
scores. However, 5' and 3' splice sites, two features that were not part of the model, show a 
much higher coverage by low SOM score regions than intronic regions, which indicates 
functional non-coding elements tend to attract fewer somatic mutations, as expected under a 
negative selection model. This effect is also observed in lncRNA, consistent with the higher 
conservation of splice junctions in this class of genes (Nitsche A, Rose D, Fasold M, Reiche 
K, 2015). Conversely, features enriched in high SOM scores (Fig. S4B) predominantly 
correspond to silent regions (intergenic, centromeres and telomeres). In summary low SOM 
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score positions tend to colocalize with functional elements and correlate with disease-causing 
mutations, suggesting the SOM model could be a significant, independent source of 
functional information on non-coding regions.  
 
Figure 6. Construction of the Somatic Mutation (SOM) model for liver cancer. A. Relative density of 
somatic mutations from whole genome sequences of 88 liver tumors (Alexandrov et al., 2013), 
associated to different genome features (see Methods for feature details). Mutation density is 
normalized so that the whole genome average has a mutation density of 1. PC gene: protein coding 
gene; CDS: coding sequence; Exon.P, Intron.P, Exon.L,Intron.L are exon and intron of protein coding 
gene and lncRNA respectively; CR: conserved region; DNase: DNase I hypersensitive site; ECS: 
evolutionarily conserved structure;  ncExon: non-coding exon; PC gene.HE, LncRNA.HE, PC 
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gene.LE and LncRNA.LE are high expressed and low expressed protein coding gene and lncRNA; PC 
gene.early, LncRNA.early, PC gene.late and LncRNA.late are early and late replicated protein coding 
gene and lncRNA; cTFBS: conserved transcription factor binding site;RR H,RR L,GC H,GC 
L,DNA.met H and DNA.met L are 1-Kb windows with high recombination rate (> 4.0), low 
recombination rate (< 0.5), high GC content (GC % > 50%), low GC content (GC%<30%), high DNA 
methylation (average value > 0.7245) and low DNA methylation (average value < 0.4062) 
respectively; Blue and red dotted lines: base lines showing average values for CDS and intergenic 
regions, respectively; B: Feature importance as measured by IncNodePurity. We only show here 
features that passed feature selection. C. Distribution of SOM scores for neutral SNPs and for clinical 
variants from two disease-causing variants databases Clivariant and HGMD. Neutral SNPs here are 
SNPs from the 1000 Genome project with allele frequency higher than 0.01, SOM scores predicted by 
the random forest model were divided by the number of patients. D. Correlation of SOM score with 
densities of disease-causing variants. Genome positions were sorted by SOM score and split into 
100Mb intervals. The plots show the average SOM score and density of disease-causing variants for 
each interval. The purple dotted line shows cutoff used for defining low SOM score thereafter. 
2.3.3 Towards an integrated model for germline and somatic mutations 
Analysis of germline and somatic mutations suggests that each mutational regime carries 
valuable independent information about selective forces acting in a tumor. We thus 
questioned whether combining SNP and SOM information at each genome position may lead 
to improved mutation prioritization in cancer. 
To assess the benefits of the joint model for scoring disease mutations, we measured disease 
variant densities in different areas of each tumor spectrum using the above cutoffs (Table S3, 
Fig S6). If we intersect high-SNP and low-SOM regions, the resulting genome area shows a 
greater enrichment in disease variants than either region taken independently (P<2.2e-16 for 
all four cancers). Therefore we argue that integrating germline and somatic mutational models 
provide a better system for prioritizing damaging mutation than any model used 
independently. 
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Figure 7. Relationship between SNP and SOM scores in liver cancer. Contours show densities of 
positions with the corresponding SNP and SOM scores. Grey dots: 1 million random genome positions; 
cyan contour: HGMD disease-causing variant positions; red contour: Clivariant positions. The top and 
right curves show marginal distributions of SNP scores (top) and SOM scores (right) for random 
genome positions, HGMD and Clivariant disease-causing variant positions. Dotted lines define cutoff 
values for hypomutated/hypermutated regions. SNP score cutoff=0.63 (98.16Mb above cutoff), SOM 
score cutoffs = 3.10 variants/Mb, defining areas below cutoff of 55.67 Mb, in liver cancer. 
Hypomutated regions defined by both cutoff correspond to ~56Mb in liver cancer type.  
Hypomutated positions are significantly over-represented within splice junctions, UTRs and 
different classes of cancer genes. We mapped predicted hypomutated positions on different 
genome features and gene types (Fig 8). As expected, functional features of protein-coding 
genes such as intron junctions and UTRs are strongly enriched for hypomutated positions (Fig 
8A). Similar trends are observed in lncRNA genes. Both lncRNA introns and exons are 
generally depleted for hypomutated regions (Fig 8), in line with poor selective pressure in 
lncRNA overall. However, lncRNA splice sites are slightly, albeit significantly, enriched in 
hypomutated regions, consistent with previous studies showing increased purifying selection 
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at lncRNA splice sites (Nitsche A, Rose D, Fasold M, Reiche K, 2015).  
We then compared hypomutated position enrichment in cancer vs. non-cancer genes. Cancer- 
protein-coding genes and cancer-related miRNAs are enriched for hypomutated regions 
compared to their non-cancer counterparts (Fig 8B, Table S4). This result suggests an 
elevated protection from somatic and germline mutations in cancer miRNAs and in the introns 
and UTRs of known cancer genes (we remind our analysis only considers the non-coding part 
of genes). However, we did not observe a significant enrichment for hypomutated regions in 
our short list of cancer-related lncRNAs (N=25). Complete lists of protein-coding, lncRNA 
and miRNA genes with their fraction of hypomutated positions are provided as suppl. files. 
Notable cancer genes with high fractions of hypomutated positions include PIM1 and MED12, 
with respectively 34% and 32% of their non-coding length that is hypomutated. Among 
cancer miRNAs, miR-1 and miR-574 are both covered almost completely by hypomutated 
positions.  
Interestingly, genes with high fractions of hypermutated positions are more divergent between 
cancer types than genes with high fractions of hypomutated positions (Fig S7), suggesting 
areas of high mutation density are largely cancer-specific, while areas of low mutation density 
tend to locate in the same functional regions of the genome. GO-term biases in these gene sets 
are significant only for genes enriched for hypermutated positions in liver cancer and CLL, 
and involve transcription regulation functions (Table S5).  
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Figure 8. Enrichment for hypomutated positions within different genome features (A) and gene 
classes (B). Positive values indicate enrichment, negative values indicate depletion. Hypomutated 
(high SNP, low SOM) positions were mapped onto genome features (A) or genes from three different 
classes (Protein-coding, lncRNA, miRNA) (B). For each feature or gene class, enrichment for 
hypomutated positions was computed as explained in Methods. As hypomutated positions are cancer-
specific, different results are obtained for each cancer class (colored dots). Shaded grey areas show 
enrichment ranges obtained from 1000 random permutations (see Methods).  
 
2.4 Discussion 
We introduced novel computational models to assess mutational constraints in the non-coding 
genome based on the presence of functional features. We trained a model on germline SNP 
data to predict rare SNP ratio at any genome site, and we trained four cancer-specific models 
on tumor data to predict somatic mutation densities. These models thus provide two 
independent measures of mutational constraints that are both relevant to the analysis of non-
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coding regions in the cancer context. Furthermore, the feature-based model construction 
enabled us to analyze the contribution of each feature to the germline and tumor mutation 
landscape and to characterize the main differences between the two mutational regimens.  
A major point we want to highlight in this study is that combining germline and somatic data 
provide an improved definition of non-coding regions that are sensitive to mutation in cancer 
cells. To illustrate this point, we extracted genome areas combining a high rare SNP ratio and 
a low somatic mutation density and showed these combined criteria are a better predictor of 
disease causing mutation than rare SNP ratio or somatic mutation density considered 
independently.  
Distinctly from current models that consider somatic mutation only as a corrective mean to 
avoid overpredicting deleterious mutations in highly mutated regions (Khurana et al., 2013; 
Lawrence et al., 2013; Fu et al., 2014), our approach thus considers somatic mutations on a 
par with evolutionary mutations, that is as a criterion to tell apart genome positions that are 
neutral (highly mutated) or under purifying selection (lowly mutated) in the tumor genome. 
We remind that prevalent forces shaping the tumor mutation landscape are the combined 
actions of mutagens and the DNA repair machinery on differentially accessible genome 
regions (Guttman et al., 2011; Schuster-Böckler and Lehner, 2012; Watson et al., 2013). 
Therefore, if functional areas are relatively spared from mutation, this is mostly not as a result 
of purifying selection, but because they are under the closer watch of DNA repair systems. 
Hence the somatic model can be viewed primarily as a way to discard regions sustaining 
accelerated mutations. However, we showed that hypomutated regions were enriched in 
functional elements such as splice junctions, which suggests purifying selection may occur as 
well.  
We are aware of the limited accuracy of somatic models when these are trained over tumors 
with low mutation rates and/or few available whole genome datasets. Currently, there are far 
fewer mutations to learn from in the tumor dataset than in the human polymorphism dataset 
(aggregate mutation densities in the present cancer datasets ranged from 20 to 600 mutations 
per Mb, vs. >12,000 SNP per Mb in the 1000 Genome data). This limits our ability to observe 
small-scale variations in mutation density. We expect that the fast accumulation of whole 
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tumor sequences will improve model accuracy within each cancer type and provide 
independent validation of our approach on other tumor classes. Another potential limitation in 
SOM models is the use of expression and epigenetic features from cell lines as a proxy for 
cancer tissues. This should also improve in the future as such information is acquired from 
primary tumor tissues.  
A key outcome of our study is a new approach to prioritize non-coding variations for cancer 
driver search. Our models predict mutational constraints at a genome position based on 
generic features, that is, largely independently of the actual mutations observed at this specific 
location. Therefore, a locus may be predicted as hypomutated by the model and yet turn out to 
sustain recurrent mutations across patients. Such a locus should then be prioritized as a 
candidate driver. Such analyses will be natural extensions of the present study.  
Although cancer research now acknowledges the importance of non-coding drivers, the search 
for cancer-related mutations has focused on regulatory elements such as promoters and 
enhancers as the key non-coding elements (Khurana et al., 2013; Ritchie et al., 2014). The 
realization that nearly 60,000 lncRNAs are expressed, often specifically, in tumoral genomes, 
many of them harboring potential disease causing mutations (Iyer et al., 2015), combined to 
the regulatory roles played by many lncRNAs (Forbes et al., 2011a) indicate that cancer 
driver search should also encompass those larger transcribed regions. Even if only 10% of 
lncRNAs are functional by conservative estimates (Ulitsky and Bartel, 2013), this corresponds 
to a much larger genome area than known regulatory elements. Currently, the search for 
cancer genes in these non-coding RNAs is driven by expression signature analysis. We show 
here that the analysis of germline and somatic mutational regimen is an important alternative 
that may lead to the identification of cancer-driving elements in ncRNA genes, as well as in 
the non-coding fraction of mRNA genes.  
 
2.5 Materials and Methods  
2.5.1 Human polymorphism, mutation and disease data 
Human polymorphism data comprising 38,248,779 SNPs were downloaded from the 1000 
Genome project pilot 1 (Clarke et al., 2012) (http://www.1000genomes.org). The data set 
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contains SNP data from 2500 individuals from about 25 world populations. SNPs with allele 
frequency lower than 0.01 were defined as rare, other SNPs were considered neutral.  
Somatic variants were collected from whole genome sequencing of paired cancer and normal 
tissues, obtained from two studies: 2,011,261 variants from 25 melanoma patients (Berger et 
al., 2012), 1,845,976 from 24 lung adenocarcinoma patients, 881,136 from 88 liver cancer 
patients and 59,993 from 28 chronic lymphocytic leukemia (CLL) patients (Lawrence et al., 
2013). Variants described as "substitution" or "indel" were both collected and are referred to 
collectively as mutations in the text.  
Curated disease-related variants were obtained from the Clivariant (Version 2014/03/03, 
55,689 variants) (Landrum et al., 2014) and HGMD (Version 2014/04/14, 166,768 variants) 
databases (Stenson et al., 2009). After exclusion of coding positions we used 13,108 HGMD 
and 6045 Clivariant mutations. 
Lists of cancer genes for Fig. 8 were obtained as follows: protein-coding cancer genes are 
from the Cancer Gene census, available from COSMIC release V71 
(http://cancer.sanger.ac.uk/cancergenome/projects/census/) (Forbes et al., 2011a); cancer-
related lncRNAs are 27 mammalian long non-coding transcripts identified from our literature 
search as experimentally associated with different cancer types (Table S6); cancer miRNAs 
are from the miRCancer database (Andersson et al., 2014).  
2.5.2 Uniform genome-wide features 
Uniform features used in all figures and models are summarized in Table S1. Human genome 
annotation (protein-coding and lncRNA genes, exons, introns, CDS, UTRs, non-coding Exons 
(ncExon) was obtained from Gencode V7 (Harrow et al., 2012). We defined as intergenic 
those regions covered by neither a protein-coding gene (including introns) nor an lncRNA. 
We defined as 5‟ and 3' splice sites intron regions spanning the first 10 nt on the 5' side and 
the last 50 nt on the 3' side. GC contents were computed directly from the HG19 human 
genome assembly.  We defined 1kb regions with > 50% GC as high GC and 1kb regions with 
< 30% GC as low GC. For the SOM model, GC contents were computed over 1Mb windows.  
Promoters, defined as regions of 2.5kb from transcription start site (TSS), are from the 
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Gerstein lab (http://funseq.gersteinlab.org/data) (Khurana et al., 2013). Enhancers are from 
the Atlas of active in vivo-transcribed enhancers, collected based on FANTOM5 CAGE data 
from multiple tissues and cell lines (Karolchik et al., 2014). TFBSs combine all transcription 
factor binding sites from more than 30 Encode cell lines (Rosenbloom et al., 2013). 
Conserved TFBS (cTFBS) are from the UCSC tfbsConsSite track established from 
human/mouse/rat alignment (Smith et al., 2013).  
"Sensitive regions" are defined in the Khurana et al. study of genome regions under purifying 
selection as the 0.4% genome fraction with highest enrichment in rare SNPs (Khurana et al., 
2013). Evolutionarily conserved regions (CR) are from the UCSC 46 mammalian genome 
alignment (Phastcons score >177) (Smith et al., 2013). Evolutionarily conserved structures 
(ECS) are RNA secondary structures predicted using comparative structure prediction 
algorithms based on multiple genome alignments (Altshuler et al., 2010). DNase I 
hypersensitive sites (DNase I) from 125 combined ENCODE cell lines were obtained directly 
from the UCSC web site (Rosenbloom et al., 2013).  
We defined early and late replication regions using the ENCODE „Repli-seq' track 
(http://genome.ucsc.edu/ENCODE) that provides signals for cell cycle fractions G1b, S1, S4, 
G2 in different cell types (Rosenbloom et al., 2013). For each protein-coding or lncRNA gene, 
we computed the early-to-late (E/L) ratio as (G1b+S1)/(S4+G2) averaged over the gene 
length. Early and late replicated genes denote genes or lncRNAs with an E/L ratio > 1 or < 1 
for all 10 cell lines respectively: Gm12878, Hela3, Hepg2, Mcf7, Imr90, K562, Bg02es, 
Huvec, Bj and SK-N-SH.  
Expression levels were calculated using number of reads per kilobase per million reads 
(RPKM). We defined as High Expression (HE) genes those with RPKM > 20 in any of the 27 
Encode cell lines (Rosenbloom et al., 2013), corresponding to the top 6% of protein coding 
genes for a single Encode cell line. 
Recombination rates (RR) are from the International HapMap Project (http://hapmap.ncbi.nlm. 
nih.gov/) (Breiman, 2001). As every genome position did not have an associated RR, we 
averaged HapMap RR values over 1kb windows. High replication rate (RRH) and low 
replication rate (RRL) regions were defined by an average replication rate above 4.0 or below 
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0.5, respectively.   
2.5.3 Tissue-specific features 
RNA expression levels, transcription factor binding sites (TFBS) and maps of histone 
modification marks were acquired from UCSC ENCODE tracks (Rosenbloom et al., 2013) for 
each cell type: Hepg2, A549, K562, Nhdfad (Table S2). Replication timings were acquired 
from UCSC ENCODE tracks for cell lines Hepg2, lmr90, K562, Bg02 (Table S2).  
To define high expression and low expression genes, expression levels were measured for a 
single randomly selected cell line from the same tissue for each independent protein coding 
gene and lncRNA. RPKM values above 20 and below 0.25 defined high (PCgene.HE, 
lncRNA.HE) and low expression genes (PCgene.LE, lncRNA.LE), respectively.  
Replication timings were defined for each protein-coding gene and lncRNA using the same 
E/L calculation as above. Genes with an E/L ratio > 1 were considered early replicated 
(lncRNA.early, PCgene.early), genes with an E/L ratio < 1 were considered late replicated 
(lncRNA.late, PCgene.late).   
DNA methylation data were obtained from TCGA database (http://cancergenome.nih.gov/) 
for cancer types liver hepatocelluar carcinoma, lung adenocarcinoma, acute myeloid leukemia 
and skin cutaneous melanoma. Average DNA methylation value was computed for each 
methylation site across multiple patients, undefined values were replaced with mean and then 
we averaged DNA methylation over non-overlapping 1Kb and 1Mb windows, 1Kb windows 
which have mean DNA methylation values greater than 0.7245 and less than 0.4062 were 
defined as high (DNA.met H) and low (DNA.met L) DNA methylation windows respectively.   
2.5.4 Rare SNP model 
A random forest (RF) is an ensemble of multiple decision trees computed from separate 
bootstrap samples of the training data and feature set (Breiman, 2001). We developed the 
germline RF model (SNP model) to predict the density of rare SNP at any genome location 
based on 14 distinct features (Table S1). The response variable was the local ratio of rare SNP 
(number of rare SNPs /total number of SNPs) obtained from the 1000 Genome Project.   
A matrix of 44130 rows was formed after removal of those combinations in coding regions, 
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each row representing one type of combination of features that can be observed throughout 
the non-coding genome. Feature selection was performed with the R VSURF package 
(Genuer et al., 2012), resulting in elimination of GC which is G or C base for each nucleotide 
and late replicated regions, 18656 combinations of the remaining 16 features. 2502 
combinations of 16 features containing 99.49% of SNPs and 99.50% of human genome were 
used to train the model after removal of the combinations of size smaller than 10Kb. The RF 
model was produced using the R randomForest package. The SNP score was predicted with 
the 16 selected features for each combination of feature in the non-coding genome. Model 
calibration and cross validation are presented in Supplementary methods. Variable importance 
was estimated using node purity, which measures the decrease in tree node purity that results 
from splits of a given variable.  
2.5.5 Somatic mutation model   
The somatic (SOM) RF model was built using as predictors the 16 uniform and 17 tissue-
specific features described in Table S1 and S2, and as response variable the local density of 
somatic mutation across all tumors in the cancer type under study. Due to the relatively sparse 
somatic mutation data, model fitting was performed using continuous variables measured for 
genome windows as explained below.  
Features ncExon, introns of lncRNAs and PC genes, CR, cTFBS, UTR, Promoter, GC 
contents and the various histone marks were expressed as the number of nucleotides covered 
by the feature within each successive 1Mb window. Features recombination rate, DNA 
methylation, replication time and expression level were computed for each successive 1Mb 
window as follows. To obtain expression levels for 1Mb windows, RNA-seq reads from each 
cell lines (3 samples/cell line) were counted, and the length of exons from Gencode 
annotation was calculated, then, average expression level was calculated as RPKM. 
Replication time in the SOM model was the average E/L ratio computed as above for each 
1Mb window. Recombination rate and DNA methylation were averaged over non-overlapping 
1-Mb windows across the genome.  
The SOM model used cancer mutation density as the response variable and the 33 genomic 
features (32 for lung cancer) as predictor variables. A matrix of 2846 rows was formed, of 
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which each row represents a 1-Mb window and columns contain values of genomic features 
and response variable. For model fitting, we discarded genome regions with poor annotation 
or biased mutation information. This included any 1Mb window overlapping a telomere, 
centromere, stalk, pericentromere, or with 100% undefined bases, and the entire Y 
chromosome due to ploidy bias (total: 224.3Mb). All predictor values were plus one and log 
scaled. 
The RF regression model was constructed with the R randomForest package as above. Feature 
selection was performed with the R VSURF package (Genuer et al., 2012). Model calibration, 
robustness testing/cross validation of the SOM models are presented in supplementary 
methods. For SOM score prediction, we used the same 1-Mb window strategy as in model 
building, however, the 1Mb-windows were slided across the human genome with a step size 
of 1Kb, in order to extrapolate to regions not used in model building. 1Mb windows with 
annotation or mutational biases were excluded as in model training, resulting in 2,832,687 
overlapping 1Mb window annotations. The SOM score was predicted using selected features 
for each 1Mb window and averaged on a 1 Kb window scale. 
2.5.6 Enrichment analysis 
Enrichment for hypomutated positions within different feature classes (Fig 8) was measured 
as the odds ratio: 
              
(
  
  
)
(
  
  
)
 
Where Hf = #hypomutated positions within feature, Sf = total size of feature, Hg = 
#hypomutated positions in whole genome, Sg = total size of genome. The significance of 
enrichment or depletion was evaluated using a permutation test as follows: a set of positions 
of same size as the hypomutated region (ie. 56Mb) was randomly sampled from the whole 
genome 1000 times, and in each random sample, enrichments were calculated for each feature 
class. The distribution of enrichment values from the 1000 random samples is shown as 
shaded areas in Figures. Only observed enrichments outside these areas are considered 
significant. Enrichment for other types of positions (hypermutated, low SOM score etc.) was 
evaluated similarly. 
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Chapter 3 –LncRNAs 
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54 
 
3.1 Introduction  
Cancer is the second leading cause of deaths in USA, about 1,658,370 new cancer incidences 
and 589,430 mortalities are estimated to occur in USA in 2015(Facts, 2015). Cancer is 
characterized by uncontrolled growth of malignant cells. Causes of cancer are complex and 
diverse, ranging from external factors such as mutagenic agents and infectious organisms to 
internal factors such as inherited mutations and immune deregulation (Gutschner and 
Diederichs, 2012).  In 2000, Hanahan and Weinberg proposed 6 critical capabilities that 
cancer cells possess to enable the malignant transformation, including sustaining proliferative 
signaling, evading growth suppressors, enabling replicative immortality, activating invasion 
and metastasis, inducing of angiogenesis and resisting cell death (Hanahan and Weinberg, 
2011).  Detection of driver genes critical to these events is a consistent goal in cancer 
genomics. Multiple bioinformatic tools have been developed to discriminate cancer-driving 
genes from background genes, such as MutSigCV (Lawrence et al., 2013) and MuSiC (Dees 
et al., 2012) which search for recurrently mutated genes across a cohort of cancer samples and 
Oncodrive-fm (Gonzalez-Perez and Lopez-Bigas, 2012) which determines driver genes 
accumulating mutations with high function effect. Up to now, 547 driver genes have been 
identified and annotated in COSMIC database (Forbes et al., 2011b). 
 
LncRNAs are a class of mRNA-like transcripts ranging from 200 bp to 100 kb, which lack 
significant open reading frames and are not translated into proteins. A recent compendium 
found 58648 lncRNAs in the human transcriptome (Iyer et al., 2015). LncRNAs are mostly 
two-exon transcripts and preferentially localized in chromatin and nucleus. They show lower 
expression and higher tissue specificity as compared to protein coding genes (Derrien et al., 
2012).  According to their genetic relation with protein coding genes, lncRNAs can be 
classified into five main categories: sense and antisense lncRNAs which are located in a 
transcript on the same or opposite strand, respectively, bidirectional lncRNAs whose 
expression and neighboring transcripts on the opposite strand are transcribed in close genomic 
proximity, intronic and intergenic lncRNAs which are derived from intronic and intergenic 
regions of transcripts respectively (Ponting et al., 2009).  
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LncRNAs were initially thought to be spurious transcriptional noise due to low RNA 
polymerase fidelity. In recent years, accumulating evidences have shown that lncRNAs are 
pervasively transcribed throughout eukaryotic genomes and involved in a wide range of 
physiological processes, such as imprinting (Jeon et al., 2012), epigenetic regulation (Mattick 
et al., 2009), apoptosis and cell cycle control (Wapinski and Chang, 2011), transcriptional 
(Orom et al., 2010) and translational regulation, splicing, cell development and differentiation 
(Clark and Mattick, 2011) and aging (Rando and Chang, 2012).  
 
Despite their lack of protein-coding capability, many lncRNAs are suspected to harbor 
biological functions. They might act through a variety of mechanisms, including chromatin 
modification, transcriptional and post-transcriptional regulation of gene expression, RNA 
splicing, and protein translation and turnover (Nie et al., 2012; Gutschner and Diederichs, 
2012) and interaction with protein and microRNAs (Ma et al., 2012) (Figure 9). As a 
consequence, deregulation of lncRNAs can play a significant role in carcinogenesis (Fang et 
al., 2014; Gupta et al., 2010; Garding et al., 2013). Here we list a number of cancer-associated 
lncRNAs, which are often aberrantly expressed and actively implicated in various tumoral 
processes in human cancer (Table 3).  
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Figure 9. Graphical display of mechanisms by which lncRNAs function in cells (Gutschner and 
Diederichs, 2012). LncRNAs can function in a variety of ways. Overall, lncRNAs are able to alter 
expression of target genes, affect protein localization and activity (D) and play an important role in the 
formation of cellular substructures (such as paraspeckles) and protein complexes (such as scaffold) 
(C;H) (Clemson et al., 2009).  (A) LncRNAs can be degraded into small endo-siRNAs, which are 
capable of silencing target gene expression. (B) LncRNAs function as “miRNA sponges”, which 
inactivate target miRNAs expression and alter the expression of downstream genes of these miRNAs 
(Wang et al., 2010). (D) LncRNAs may function via interaction with proteins, for instance, NRON 
(non-coding repressor of NFAT) can bind to the transcription factor NFAT (nuclear factor of activated 
T cells) and transport NFAT from nuclear to cytoplasm, which suppresses NFAT target gene 
expression (Willingham et al., 2005). (E) Moreover, lncRNA may either recruit or block transcription 
factors to bind to target gene promoters, which leads to activation or degradation of target gene 
transcription (Feng et al., 2006; Martianov et al., 2007). (F) LncRNAs can modulate alternative 
splicing of target mRNAs via formation of the spliceosome complex (Beltran et al., 2008). (G) 
LncRNAs may also participate in the epigenetic regulation, they can regulate chromatin status via 
interaction with chromatin remodeling complexes or histone modification (Rinn et al., 2007; Zhao et 
al., 2008).  
  
3.2 LncRNAs and proliferation 
One important feature that cancer possesses is unlimited growth without the stimulation of 
external factors. Normal cells are able to produce proliferation promoting or inhibiting factors 
which tightly control the number of cells and functions, however, malignant tumor cells are 
able to escape from proliferation signals and obtain uncontrolled growth through a wide range 
of ways, such as hypoxia, dysregulation of cell cycle genes such as the Rb pathway (INK4-
cyclin D-cdk4/6-Rb) and Cyclins D and E as well as activation of signaling pathways such as 
Wnt/β-catenin signaling, PI3K/Akt/mTOR signaling, Notch signaling and NF-κB signaling 
(Feitelson et al., 2015). In the past ten years, there was increasing evidence demonstrating 
lncRNAs affect the proliferation of cancer cells.  Sun et al. (Sun et al., 2015) used GRO-seq 
and RNA-seq to annotate lncRNAs in MCF-7 breast cancer cell line and found about 1900 
lncRNAs, more than 700 of which are newly identified lncRNAs. LncRNA152 and 
lncRNA67 were functionally characterized further in breast cancer, these two lncRNAs are 
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upregulated in breast tumors. Silencing their expression by siRNA-mediated deletion greatly 
inhibited cellular proliferation in MCF-7 and T47D breast cancer cell-lines. In contrast, 
enhanced expression of LncRNA152 and lncRNA67 in part rescued the growth inhibition by 
siRNA knockdown in MCF-7 cells. In addition, LncRNA152 and lncRNA67 are implicated in 
the regulation of cell cycle and estrogen receptor pathway. Knockdown of either lncRNA 
increased the number of cells in G1 phase and reduced the fraction of cells in S phase. Most 
importantly, lncRNA152 and lncRNA67 interacted with estrogen signaling pathway, which 
might in part account for their control of cell cycle.  Sun et al (Sun et al., 2015) found that 
estrogen affected the expression of lncRNA152 and lncRNA67, with lncRNA152 upregulated 
and lncRNA67 downregulated. Estrogen treatment in part reduced the inhibitory effect on 
cellular growth of MCF-7 by knockdown of lncRNA152; however, silencing of either 
lncRNA repressed the expression of many estrogen-regulated target genes. Another evidence 
of lncRNAs playing a role in cancer proliferation is PCAT-1 (prostate cancer associated 
transcript 1). PCAT-1 is overexpressed in high-grade and metastatic prostate cancer samples. 
Knockdown and enhanced expression of PACT-1 led to decreased proliferation rate and 
modest increase in cellular growth, respectively. In addition, downregulation of PCAT-1 by 
siRNA-mediated knockdown caused deregulation of 370 protein-coding genes, among which 
255 are upregulated and 115 downregulated. Gene ontology enrichment analyses found that 
upregulated genes were related to cell cycle and mitosis, suggesting that PCAT-1 might 
contribute to proliferation through transcriptional regulation of cell cycle and mitosis-
associated genes in prostate cancer (Prensner and Chinnaiyan, 2011). 
An alternative mechanism sustaining proliferation involves cancer cells that are able to escape 
proliferation suppression operated by tumor suppressor genes, such as TP53, PTEN and RB. 
External or internal stimuli, such as radiation and hypoxia activate these tumor suppressor 
genes, leading to cell cycle disruption or apoptosis.  Recent studies have shown that lncRNAs 
are involved in the inhibition of tumor suppressor genes in diverse ways.  H19, located on 
chromosome 11p15.5, is markedly increased in gastric cancer cell lines and cancer samples. 
Enhanced H19 expression decreases P53 activity and protein levels of the p53 target Bax, 
leading to promotion of cell proliferation and reduction of cell apoptosis (F. Yang et al., 2012). 
Expression of Alu-mediated p21 transcriptional regulator (APTR) is negatively correlated to 
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that of p21 in gliomas. APTR inhibits the transcription of CDKN1A/p21 via recruitment of 
the PRC2 complex to the promoter of CDKN1A/p21, leading to activation of cell 
proliferation in HCT116 and to G1-S arrest in MCF10A cancer cells. The localization of 
APTR to the p21 promoter is mediated by the Alu (c-Alu) element embedded in APTR. 
Expression of p21 is induced and expression of APTR is reduced irrespective of p53 activity 
in human glioma cells, in response to cell stresses, such as heat shock and doxorubicin. This 
body of evidence supports that APTR represses p21 epigenetically via recruiting PRC2 to the 
p21 promoter (Negishi et al., 2014). 
 
3.3 LncRNAs and invasion and metastasis 
Cancer cells are able to invade and metastasize to form secondary tumors, which makes 
treatment of cancer highly challenging and causes high mortality rate. In order to successfully 
invade into healthy tissues, cancer cells have to go through multiple processes, including 
morphological changes, transition through lymphatic system and blood vessels and formation 
of micrometastases, eventually formation of a secondary tumor (Gutschner and Diederichs, 
2012). Epithelial mesenchymal transition (EMT) is a developmental regulatory process which 
plays a great role in the regulation of cancer invasion and metastasis (Yilmaz and Christofori, 
2009; Polyak and Weinberg, 2009).  During EMT, epithelial cells that are non-mobile, 
polarized, embedded via cell-cell junctions are transformed into invasive mesenchymal cells 
that are individual, non-polarized and mobile. Several important factors are critical to the 
EMT process, such as E-cadherin (CDH1) and N-Cadherin (CDH2). As a critical cell-to-cell 
adhesion molecule, E-cadherin is frequently downregulated or inactivated in human cancers 
(Berx and van Roy, 2009; Cavallaro and Christofori, 2004).  Upregulation of E-cadherin 
therefore represses cancer invasion and metastasis, E-cadherin is under strict control by 
multiple factors, such as Snail1 (Snail), Snail2 (Slug), ZEB1 (δEF1), 
ZEB2 (Sip1), E47, and Twist which are transcriptional repressor of E-cadherin (Peinado et al., 
2007) and receptor tyrosine kinase or Src which mediates phosphorylation and degradation of 
E-cadherin (Beltran et al., 2008; Yilmaz and Christofori, 2009). N-Cadherin (CDH2), that is 
normally expressed in nervous tissues and mesenchymal cells, forms homophilic cell-cell 
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adhesion junctions. Its expression can be upregulated by collagen I, α2β1-integrin and Twist 
(Alexander et al., 2006; Shintani et al., 2008). 
 
An increasing number of evidences show lncRNAs are implicated in cancer invasion and 
metastasis in a variety of ways. The exemplary lncRNA MALAT1 (Metastasis-Associated 
Lung Adenocarcinoma Transcript 1, MALAT-1) shows abundant expression in diverse cell 
types and high conservation across various species (Gutschner et al., 2011; Tripathi et al., 
2010). MALAT1 is upregulated in several cancer types including lung cancer, uterine 
endometrial stromal sarcoma and hepatocellular carcinoma (Ji et al., 2003; Guo et al., 2010; 
Lin et al., 2007; Tano et al., 2010).  MALAT1 plays an active role in cancer metastatic 
process, for instance, it regulates motility-associated genes and enhances cellular motility of 
lung cancer cells, depletion of MALAT1 by siRNAs reduces the expression of CTHRC1, 
CCT4, HMMR or ROD1, which impairs cell motility in lung adenocarcinoma (Tano et al., 
2010). Nude mice with depletion of MALAT1 expression developed less number of lung 
tumor nodules and metastases (Schmidt et al., 2011; Gutschner et al., 2013).  Moreover, 
MALAT1 also promotes cellular proliferation and metastasis of cervical cancer cells, 
silencing MALAT1 expression results in deregulation of apoptosis pathway related genes, 
such as caspase-8, caspase-3, Bcl-2 and Bcl-xL in cervical cancer (Guo et al., 2010).  
MALAT1 is involved in the regulation of epithelial-mesenchymal transition (EMT) 
associated genes, Downregulation of  MALAT1 expression leads to downregulation of ZEB1, 
ZEB2 and Slug and upregulation of E-cadherin in bladder cancer, which induces epithelial-to-
mesenchymal transition and metastasis in bladder cancer (Ying et al., 2012).  
Another cancer metastasis-associated lncRNA is HOTAIR (HOX Antisense Intergenic RNA), 
HOTAIR expression is upregulated in primary and metastatic tumors of different cancer types, 
including breast cancer (Gupta et al., 2010), colorectal cancer (Kogo et al., 2011), pancreatic 
cancer (Kim et al., 2013), hepatocellular carcinoma (Geng et al., 2011), gastrointestinal 
stromal cancer (Niinuma et al., 2012) and oesophageal squamous cell carcinoma (X. Li et al., 
2013). HOTAIR expression is high in breast cancer that are predisposed to metastasize, and 
its inhibition blocks metastasis in mouse models (Gupta et al., 2010). HOTAIR plays an 
important role in epigenetic regulation, enhanced expression of HOTAIR interacts with PRC2 
(polycomb repressive complex 2) to alter H3K27 methylation , leading to changes of target 
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gene expression in epithelial breast cancer cell and increased cancer metastasis, in contrast,  
knockdown of HOTAIR suppresses cancer invasion and metastasis (Gupta et al., 2010). 
HOTAIR expression is upregulated in hepatocellular carcinoma compared to adjacent normal 
tissues, increased expression of HOTAIR indicates recurrent HCC and poor survival (Yang et 
al., 2011), furthermore, HOTAIR might serve as a potential indicator of lymph node 
metastasis in liver cancer; downregulation of HOTAIR expression greatly leads to decreased 
cellular metastasis and viability in liver cancer cells (Geng et al., 2011). 
The third metastasis-involved lncRNA is H19, upregulation of H19 expression is observed in 
hepatocellular carcinoma (Matouk et al., 2007), bladder cancer (Luo et al., 2013) and lung 
cancer (Matouk et al., 2014). H19 has been demonstrated to actively contribute to tumoral 
metastasis and invasion through multiple mechanisms. H19 directly affects the expression of 
the key players of EMT process, H19 expression is negatively correlated with E-cadherin and 
assists in binding of Ezh2, an epigenetic regulator, to the promoter of E-cadherin and 
indirectly activates Wnt-βcatenin, which leads to transcriptional repression of E-cadherin in 
bladder cancer (Luo et al., 2013).  Moreover, H19 suppresses E-cadherin expression through a 
positive feedback loop between Slug and H19/miR-675, in which H19 induces Slug 
expression through miR-675-implicated mechanism, and upregulation of Slug further 
activates H19 promoter and enhances H19 expression levels in lung cancer  (Matouk et al., 
2014).  H19 is also shown to regulate tumor metastasis via epigenetic activation of miR-200 
family in liver cancer, ectopic expression of H19 interacts with the HnRNPU/PCAF/RNA 
PolII complex and enables the binding of the complex to the promoter of miR-200 family, 
which activates miR-200 family via enhancing histone H3 acetylation, thus H19 can 
epigenetically activate the miR-200 pathway, leading to induction of mesenchymal-to-
epithelial transition and the inhibition of cancer metastasis (L. Zhang et al., 2013).  
 
3.4 LncRNAs and apoptosis 
Apoptosis plays an important role in a wide range of diseases, including cancer.  Cells initiate 
apoptotic processes in response to external stimuli, such as glucocorticoids, radiation, hypoxia 
and infection. Apoptotic processes are executed by two main mechanisms, including the 
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extrinsic death receptor pathway and the intrinsic mitochondrial apoptosis pathway. The 
extrinsic pathway mainly consists of three parts: the death ligands, such as tumor necrosis 
factor and Fas ligand, transmembrane receptors, such as the type I TNF receptor and Fas 
receptor as well as adaptor proteins, such as Fas-associated death domain and TNF receptor-
associated death domain. Death ligands bind to the extracellular domain of transmembrane 
receptors, and the death receptors interact with adaptor proteins, which leads to the formation 
of a death-inducing signaling complex (DISC) between Pro-caspase-8 and adaptor proteins 
and activation of Pro-caspase-8 (Khosravi-Far and Esposti, 2004). The mitochondrial 
apoptosis can be achieved in many ways. DNA damage initiates apoptosis through activating  
the tumor-suppressor protein p53, which consequentially upregulates the expression of pro-
apoptotic genes such as DR-5, BAX, BAK, NOXA, PUMA and downregulates the expression 
of anti-apoptotic genes such as Bcl-2 and survivin (Goldar et al., 2015). Moreover, 
intracellular stimuli can affect the permeability of mitochondrial membrane, initiate 
mitochondrial swelling via the BCL-2 family which includes 25 pro- and anti-apoptotic 
members (Chipuk et al., 2004). The imbalance among these pro-apoptotic and anti-apoptotic 
Bcl-2 family members increases the permeabilization of mitochondrial membranes and leads 
to leakage of cytochrome C and other mitochondrial proteins. For instance, the release of 
mitochondrial proteins such as SMACs (second mitochondria-derived activator of caspases) 
deactivates inhibitor of apoptosis proteins (IAPs) and indirectly promotes the activities of 
caspases; another apoptotic protein , cytochrome c, is released by mitochondria through the 
formation of the mitochondrial apoptosis-induced channel (MAC). Cytochrome C together 
with apoptotic protease activating factor-1 and ATP form a complex “apoptosome”, which 
transforms pro-caspase-9 into its active form of caspase-9, activates caspase-3 and eventually 
results in cell death (Zou et al., 1997; Jin et al., 2005).   
A number of lncRNAs has been observed to affect cancer apoptosis pathways, such as 
PCGEM1, CUDR and PANDAR. PCGEM1 is overexpressed and shows anti-apoptotic effect 
in prostate cancer (Srikantan et al., 2000). Overexpression of PCGEM1 led to expression 
delay of p53 and p21 and remarkably decreased cleaved caspase 7 and PARP expression in 
doxorubicin-treated LNCaP cells.The apoptotic inhibition is highly androgen-dependent, as 
mutations of androgen could diminish this effect (Liebert and Gene, 2006). Another anti-
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apoptotic lncRNA is CUDR (cancer upregulated drug resistant) displaying inhibitory effect on 
drug-induced apoptosis, such as doxorubicin and etoposide in squamous carcinoma cells 
A431. Enhanced expression of CUDR downregulates the effector caspase 3, which might 
account for this inhibitory function of apoptosis (Jin et al., 2005; Khosravi-Far and Esposti, 
2004). 
However, many lncRNAs play a pro-apoptotic role in cancer, such as PANDAR (Han et al., 
2015), INXS (DeOcesano-Pereira et al., 2014) and GAS5 (Kino et al., 2010). PANDAR is 
lowly expressed in non-small cell lung carcinoma (NSCLC), and downregulation of 
PANDAR expression correlates negatively with great tumor size and late tumor stage. 
Enhanced expression of PANDAR could greatly increase the apoptosis rate of lung cancer 
cell lines, A549 and SPC-A1, the apoptosis-inducing effect is in part rescued by upregulation 
of P53. Overexpression of PANDAR could induce the expression of pro-apoptotic proteins 
(Bax and Bad) and inhibit anti-apoptotic protein (Bcl-2), which leads to the activation of 
caspase-3 and induction of apoptosis in NSCLC cells (Han et al., 2015). 
 
INXS is a 1903 nts pro-apoptotic lncRNA that is transcribed from the opposite strand of the 
BCL-X genomic locus, INXS is significantly less abundant in kidney cancer in comparison 
with adjacent normal tissues. Treatment of apoptosis-inducing agents, UV-C light exposure 
and anti-cancer agent sulforaphane (SFN), led to increased expression of INXS and activation 
of caspases 3, 7 and 9 in 786-O kidney tumor cells, siRNA-mediated deletion of INXS could 
greatly diminish such an effect. Overexpression of INXS resulted in a pronounced 
accumulation of pro-apoptotic BCL-XS and activated activation of caspases 3, 7 and 9 as well 
as a decrease of anti-apoptotic BCL-XL abundance, thus inducing apoptosis in 786-O cells. 
Furthermore, tumor weight was reduced by increased BCL-XS expression after injection of 
INXS-expressing plasmid in mouse xenograft model. All these evidences support that INXS 
is an apoptosis-inducer in kidney cancer (DeOcesano-Pereira et al., 2014). 
GAS5 (Growth Arrest-Specific 5), firstly identified in mouse NIH3T3 fibroblasts, is 
downregulated in various cancer types, such as leukemia and breast cancer (Coccia et al., 
1992; Schneider et al., 1988). GAS5 interacts with DNA binding domain of the glucocorticoid 
receptors and blocks the DNA glucocorticoid response elements to bind these receptors, 
which inhibits the glucocorticoid-mediated transcription of anti-apoptotic genes like cellular 
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inhibitor of apoptosis 2 (cIAP2) and leads to cellular apoptosis (Kino et al., 2010). 
 
3.5 LncRNAs and cell cycle 
The cell division cycle consists of quiescent/senescent (G0) phase, Interphase (G1, S and G2 
phase) and Cell division (M) phase. The G0 phase is a resting phase in which cells have 
finished division. Interphase is the stage where cells prepare for mitosis, including the G1 
phase which supplies proteins and increases the number of organelles. The S phase is that for 
DNA synthesis, and the G2 phase is that for cell growth. Lastly, cell growth stops and cells 
are divided into two daughter cells in the M phase. The cell cycle is under strict regulation of 
cyclin-dependent kinases (CDKs) and their related pathways in mammalian cells. The CDKs 
bind to cyclins, including cyclins A, B, D, and E, and form CDK-cyclin complexes which 
phosphorylate and activate their target genes, enabling cell cycle progression (Morgan, 1995).  
For instance, in response to extracellular signals, such as growth factors, Cyclin D binds to 
CDK4 and forms the cyclin D-CDK4 complex which in turn phosphorylates the 
retinoblastoma susceptibility protein (Rb) and its family members, p107 and p130 and 
activates E2F transcription in the late G1 phase. The activation of E2F leads to activation of 
multiple growth-promoting genes such as cyclin E, DNA polymerase (Weinberg, 1995; 
Kitagawa et al., 1996). Cyclin E-CDK2 phosphorylates pRB as well as several proteins 
involved in DNA replication to push the cell from G1 to S phase (Hwang and Clurman, 2005). 
Moreover, the cell cycle is negatively regulated by CDK inhibitors, such as p15, p16, p18, 
p21, p27, and p57 which inhibit the activities of cyclin–CDK complexes through specific 
binding to their targets (Sherr and Roberts, 1999; Vidal and Koff, 2000). 
A number of lncRNAs plays important roles in the progression of the cancer cell cycle 
through regulation of expression of critical cell cycle genes, such as Purα, CDKs and cyclins 
(Bida et al., 2015; Liu et al., 2012; Tripathi et al., 2013). MA-linc1 (Mitosis-Associated Long 
Intergenic Non-Coding RNA 1) locates on the chromosome 5 and consists of three exons,  it 
functions as a transcriptional target gene of E2F1. Knockdown of MA-linc1 alters cell cycle 
distribution of the human osteosarcoma cell line U2OS, characterized by a reduction of G1 
phase cells and an increase in cancer cells at G2/M and S phase. Moreover, silencing 
expression of MA-linc1 led to decreased mitosis exit in M phase-arrested cells. The 
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mechanism underlying the cell cycle regulation of MA-linc1 can be partly mediated by cis 
repression of the expression of its neighboring gene Purα (DeOcesano-Pereira et al., 2014), 
which is often deleted in cancers and whose aberrant expression arrests cell cycle progression 
(Bida et al., 2015; Gallia et al., 2000). In support of the above findings, knockdown of MA-
linc1 induces cellular apoptosis initiated by the antimitotic drug, Paclitaxel and deletion of 
Purα could rescue such an enhancement of apoptosis (Bida et al., 2015). 
The gadd7 (growth-arrested DNA damage-inducible gene 7) lncRNA (DeOcesano-Pereira et 
al., 2014) is another important lncRNA that controls cell-cycle progression. It was firstly 
identified from Chinese hamster ovary (CHO) cells owing to its abundant expression after UV 
irradiation (Hollander et al., 1996). Depletion of gadd7 leads to an increase of cellular 
proliferation and cell cycle redistribution, with a remarkable reduction of G1 phase cells and 
an accumulation of G2/M and S phase cells in response to DNA damage caused by UV 
radiation, suggesting that gadd7 may affect G1/S transition. Following UV radiation, gadd7 
expression is induced and it directly binds to TAR DNA-binding protein (TDP-43) and 
dissociates TDP-43 from cyclin-dependent kinase 6 (Cdk6) mRNA, which leads to Cdk6 
mRNA decay and the regulation of G1/S checkpoint (Liu et al., 2012). 
P53, as a tight regulator of the cell cycle, is able to control both G1 and G2/M checkpoints 
(Schwartz and Rotter, 1998).  Many lncRNAs function as cell cycle regulators via P53-
mediated cell cycle control (Léveillé et al., 2015;Sánchez et al., 2014) , such as PR-lncRNA-1, 
PR-lncRNA-10 and RoR. PR-lncRNA-1 and PR-lncRNA-10, localized in the nucleus of cells, 
are two transcriptional targets of P53. Gene expression analysis revealed that PR-lncRNA-
1and PR-lncRNA-10 depletion led to dysregulation of several genes associated to cell cycle 
control and apoptosis, which are p53 downstream target genes. Moreover, PR-lncRNA-1 and 
PR-lncRNA-10 are essential to the binding of p53 to p53 target genes, such as SERPINB5, 
CDKN1A, BCL2L1and BBC3 genes. Silencing the expression of PR-lncRNA-1and PR-
lncRNA-10 caused a significant increase of cell proliferation, and decrease of cell apoptosis. 
Deletion of PR-lncRNA-1 and PR-lncRNA-10 increased the number of cells in S-phase of 
cell cycle in HCT116 cells. Overall, these findings support that PR-lncRNA-1 and PR-
lncRNA-10 contribute to an induction of apoptosis and cell cycle arrest via the p53 signaling 
pathway (Ji et al., 2003; Guo et al., 2010; Lin et al., 2007; Tano et al., 2010; Sánchez et al., 
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2014).  Another lncRNA named RoR interacts with the heterogeneous nuclear 
ribonucleoprotein I (hnRNP I) through binding of hnRNP I to a 28-base RoR motifs, which 
enables to suppress the expression of p53 in response to ultraviolet C (UVC). As a result, RoR 
reduced the p53-mediated apoptosis in MCF-7 cells and G2/M arrest in HCT-116 WT cells 
(A. Zhang et al., 2013). 
 
Table 3. A list of experimentally characterized cancer-related lncRNAs  
 LncRNA Expression Cancer type Function Reference 
Proliferation LncRNA152  
lncRNA67 
Up-regulated breast cancer growth-promoting (Sun et al., 2015) 
PACT-1 Up-regulated Prostate cancer growth-promoting (Prensner et al., 
2011) 
APTR  Colon cancer, glioblastoma growth-promoting (Negishi et al., 
2014) 
H19 Up-regulated  Hepatocellular, bladder, lung 
cancer, breast and gastric 
cancer 
growth-promoting, metatasis 
inducer 
(Matouk et al., 2007; 
Barsyte-Lovejoy, 
2006; Berteaux et 
al., 2005; F. Yang et 
al., 2012; Luo et al., 
2013; Matouk et al., 
2014)   
Sox2ot  Up-regulated Lung squamous cell 
carcinomas (SCCs) 
growth-promoting  (Hou et al., 2014) 
GAS5 Down-regulated  Leukemia,non-small-cell lung 
cancer,bladder cancer 
growth-inhibiting, apoptosis 
inducer 
(Braconi et al., 
2010; Coccia et al., 
1992; Shi et al., 
2013; Z. Liu et al., 
2013) 
HULC Up-regulated  Liver,gastric cancer miR-372 sponge, growth-
promoting, metasasis inducer 
and apoptosis inhibitor 
(Wang et al., 2010; 
Zhao et al., 2014) 
PCNA-AS1 Up-regulated Hepatocellular carcinoma 
 
growth-promoting 
(Yuan et al.,2014) 
PRNCR1 Up-regulated Prostate cancer growth-promoting (Chung et al., 2011) 
ANRIL Up-regulated Prostate cancer, acute 
lymphoblastic leukemia, 
glioma, melanoma 
growth-promoting (Yap et al., 
2010;Cunnington et 
al., 2010; Iacobucci 
et al., 2011) 
T-UCR uc.338 Up-regulated  Liver cancer  growth-promoting (Braconi et al., 
2010) 
SPRY4-IT1 Up-regulated  Melanoma growth-promoting, apoptosis 
inhibitor 
(Khaitan et al., 
2011) 
PlncRNA-1  Up-regulated Esophageal squamous 
carcinoma 
growth-promoting (Wang et al., 2014) 
HNF1A-AS1 Up-regulated Oesophageal adenocarcinoma growth-promoting ,metasasis 
inducer 
(X. Yang et al., 
2014) 
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ncRAN Up-regulated Bladder cancer growth-promoting ,metasasis 
inducer 
(Zhu et al., 2011) 
GHET1  Up-regulated  Gastric and bladder cancer growth-promoting (F. Yang et al., 
2014; Li et al., 2014) 
LOC285194  
BC040587 
Down-regulated Osteosarcoma,colon cancer growth-inhibiting (Q. Liu et al., 2013; 
Pasic et al., 2010) 
PTENP1  PTENP1 locus is selectively 
lost in human cancer 
growth-inhibiting (Poliseno et al., 
2010) 
MEG3 Down-regulated  Brain cancer, non-small cell 
lung cancer 
growth-inhibiting (Zhang et al., 
2003;Lu et al., 2013) 
HOTTIP Up-regulated Pancreatic cancer growth-promoting, metasasis 
inducer, apoptosis inhibitor 
(Cheng et al., 2015) 
PCAN-R1  
PCAN-R2 
Up-regulated Prostate cancer growth-promoting (Du et al., 2013) 
 ARLTS1 Down-regulated Lung cancer growth-inhibiting (Yendamuri et al., 
2007) 
Metastasis  MALAT1 Up-regulated  lung cancer, uterine 
endometrial stromal sarcoma, 
cervical cancer and 
hepatocellular carcinoma 
Metatasis inducer (Ji et al., 2003; Guo 
et al., 2010; Lin et 
al., 2007; Tano et 
al., 2010).  
 HOTAIR  Up-regulated  Breast cancer,liver cancer 
  
Metastasis inducer (Gupta et al., 2010; 
Geng et al., 2011) 
 BANCR Up-regulated  Melanoma Metatasis inducer (Flockhart et al., 
2012) 
 UCA1 Up-regulated Tongue squamous cell 
carcinoma 
Metasasis inducer  (Fang et al., 2014) 
 lncRNA-EBIC Up-regulated Cervical cancer Metasasis inducer  (N. Sun et al., 2014) 
 AOC4P Down-regulated Hepatocellular carcinoma Metasasis inhibitor (Wang et al., 2015) 
 ZEB1-AS1 Up-regulated  Hepatocellular carcinoma Metasasis inducer (Li et al., 2015) 
 lnc-ATB Up-regulated Breast cancer Metasasis inducer (Shi et al., 2015) 
 HNF1A-AS1 Up-regulated  Lung cancer Metasasis inducer (Wu et al., 2015) 
 DRAIC/PCAT29 Down-regulated Prostate cancer Metasasis inhibitor (Sakurai et al., 2015) 
 HOTTIP and 
HOXA13 
Up-regulated Hepatocellular carcinoma Metasasis inducer (Quagliata et al., 
2014) 
 treRNA Up-regulated Breast cancer Metasasis inducer (Gumireddy et al., 
2013) 
 ESCCAL-1 Up-regulated Esophageal squamous cell 
carcinoma (ESCC) 
Metasasis inducer, apoptosis 
inhibitor 
(Hao et al., 2015) 
 NKILA Down-regulated Breast cancer Metasasis inhibitor (Liu et al., 2015) 
Apoptosis  PCGEM1 Up-regulated Prostate cancer Apoptosis inhibitor, growth-
promoting 
(Petrovics et al., 
2004) 
CUDR Up-regulated Human squamous cancer Apoptosis inhibitor 
(Jin et al., 
2005;Khosravi-Far 
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and Esposti, 2004). 
 PANDAR Down-regulated non-small cell lung carcinoma 
(NSCLC) 
Apoptosis inducer 
(Han et al., 2015) 
INXS Down-regulated Kidney cancer Apoptosis inducer 
(DeOcesano-Pereira 
et al., 2014) 
TUG1 Up-regulated Hepatocellular carcinoma 
(HCC) 
Apoptosis inducer, growth-
promoting 
(M. Huang et al., 
2015) 
uc.73a Up-regulated Leukemia, colorectal cancer Apoptosis inducer (Calin et al., 2007) 
uc002mbe.2  Liver cancer Apoptosis inducer (H. Yang et al., 
2013) 
LincRNA-p21  Lung cancer, sarcoma, 
lymphoma 
Apoptosis inducer (Huarte et al., 2010)( 
 AK126698 Down-regulated  Non-small-cell lung cancer Apoptosis inducer (Y. Yang et al., 
2013) 
Cell cycle MA-linc1   osteosarcoma Cell cycle G1 phase arrest, 
apoptosis inducer 
((Bida et al., 2015) 
 gadd7  CHO-K1 cells (Hamster 
Chinese ovary) 
G1/S checkpoint, growth-
inhibiting 
(Liu et al., 2012) 
 PR-lncRNA-1 and 
PR-lncRNA-10 
Down-regulated Colorectal cancer Cell cycle G1 phase arrest, 
apoptosis inducer, growth-
inhibiting  
(Sánchez et al., 
2014) 
 lincRNA-RoR 
(RoR) 
 Breast cancer, colon cancer   Inhibition of G2/M arrest, 
apoptosis inhibitor, 
(A. Zhang et al., 
2013) 
 Linc00152 Up-regulated Gastric cancer Cell cycle G1 phase arrest, 
growth-promoting , apoptosis 
inhibitor 
(Zhao et al., 2015) 
 lncRNA-HEIH Up-regulated Hepatocellular carcinoma 
(HCC) 
G0/G1cell cycle arrest (Yang et al., 2011) 
Others DD3(PCA3) Up-regulated Prostate canccer A diagnostic marker (Kok et al., 2002) 
 XIST Lost in 
female breast, 
ovarian, and 
cervical cancer 
cell lines 
Breast, ovarian, and cervical 
cancer 
X chromosome silencing (McHugh et al., 
2015) 
 
3.6 Development of computational tools for functional lncRNA prediction 
Through gene regulation or other mechanisms, lncRNAs are emerging as important players in 
the cancer paradigm, acting as proto-oncogenes, tumor suppressor genes and drivers of 
metastatic transformation. Even though an increasing number of lncRNAs have been 
functionally characterized, the biological functions of the majority of lncRNAs remain 
unknown. Therefore, bioinformatics tools are urgently needed to prioritize cancer-related 
lncRNAs. Currently, more and more studies are being developed to explore methods to 
identify either cancer or disease-related lncRNAs. Table4 summarizes the computational 
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approaches used to predict functional lncRNAs. 
3.6.1  Recurrent Somatic Copy-number Alteration-based Approach  
Du et al. selected lncRNAs in recurrent somatic copy-number alterations (SCNAs) (gain) 
regions as candidate drivers, such as PCAN-R1 or PCAN-R2 which are the two most 
significantly differentially expressed lncRNAs between tumor and normal prostate tissues. 
Knockdown of them resulted in substantial decrease in both cell growth and colony formation 
in the androgen-dependent prostate cancer cell line LNCaP, suggesting they have tumor-
promoting functions in prostate cancer (Du et al., 2013).  
3.6.2  Coexpression with Coding Genes Approach 
Guttman et al. have developed a coexpression based method to functionally characterize 
lncRNAs. They ranked protein coding genes according to their correlation coefficients of 
expression levels with each lncRNA, and then performed a Gene Set Enrichment Analysis 
(GSEA) on high ranking genes to identify function enrichment for each lncRNA. Application 
of this coexpression method to 1,600 lncRNAs found that lncRNAs are actively implicated in 
a wide range of functional processes, including cell proliferation, development and embryonic 
stem cell pluripotency(Guttman et al., 2009).  
Liao et al constructed a coding–non-coding gene co-expression (CNC) network which 
employs two different strategies to predict functions of lncRNAs, including the network hub-
based method and network modules. The hub-based method determines lncRNA functions 
based on gene ontology (GO) enrichment analysis of surrounding protein coding genes. The 
authors use a Markov cluster algorithm (MCL) to search for coexpressed functional modules 
composing either non-coding or coding genes in the CNC network, and then assign functions 
to lncRNAs based on module functions. Application of the CNC method to 340 mouse 
lncRNAs found these lncRNAs have functions involving organ or tissue development, 
cellular transport, and metabolic processes (Liao et al., 2011). Liu et al developed a 
computational framework to prioritize disease-associated lncRNAs based on lncRNA, gene 
expression profile and gene-disease association data. They obtained expression profiles of 
21626 lincRNAs generated by RNA-sequencing of 22 human tissues or cell types (Karolchik, 
2004), 17080 genes from RNA sequencing of 73 human tissue or cell types (Su et al., 2004) 
and gene-disease associations from the DisGeNET database (Bauer-Mehren, 2010). They first 
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associated lncRNAs to tissue-specific diseases by combining high tissue specificity scores and 
high expression levels of lncRNAs in that tissue. Secondly, for non-tissue-specific lncRNAs, 
Spearman rank correlation coefficients were calculated between protein coding genes and 
each lncRNA to obtain a set of co-expressed genes. The hypergeometric distribution test for 
the set of genes co-expressed with each lncRNA was then used to predict potential lncRNA-
associated diseases (Liu et al., 2014). Implementation of this computational framework 
enabled identification of 2272 potential lincRNA-associated diseases and novel lncRNAs for 
human diseases. 
3.6.3  Network-based systems 
Long non-coding RNA global function predictor („lnc-GFP‟) integrates gene expression and 
protein interaction data to functionally annotate lncRNAs. The authors use a bi-colored 
network in which vertices represent protein-coding genes and lncRNAs, and edges stand for 
co-expression and protein interaction. lnc-GFP uses a global propagation algorithm in which 
„function flow‟ from known function annotations for genes propagates on the network 
iteratively.  The association score measuring how likely an unknown lncRNA can be 
functionally annotated combines the iterative propagation of the „function flow‟ on the 
network and the previous knowledge score calculated between an unknown lncRNA and a 
given functional category (Guo et al., 2013). The authors claimed lnc-GFP is able to 
functionally characterize 94.9% of lncRNAs in their bi-colored network. 
3.6.4  Interaction with Proteins and miRNAs Approach 
Interaction of lncRNAs with proteins and miRNAs is a major path towards understanding the 
function of lncRNAs. Several methods have been developed to explore interactive properties 
of lncRNAs with proteins and miRNAs and indirectly predict their functions. Bellucci  et al 
have developed catRAPID to assess the interaction propensities of lncRNAs with proteins 
using their physicochemical properties, including secondary structure, hydrogen bonding and 
van der Waals. The catRAPID method was trained on 592 protein-RNA pairs from the Protein 
Data Bank (Bellucci et al., 2011). catRAPID has a prediction accuracy of 0.89, which is 
validated with experimentally supported protein associations annotated in the NPInter dataset 
(Wu, 2006). Jeggari et al have developed the program miRcode which aims to predict putative 
target sites of microRNAs in 10,419  lncRNAs. The miRcode program is constructed mainly 
based on two criteria, complementarity to seed regions, the 2rd-8th bases from the 5′-end of 
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the microRNA, and evolutionary conservation, as assessed from 46 vertebrate genome 
alignments (Jeggari et al., 2012). 
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Table 4. Summary of computational approaches for predicting disease or cancer related 
functional lncRNAs  
 
Even though much has been done to predict functional lncRNAs based on different algorithms, 
the computational prediction of lncRNA function is still in its infancy. Current methods 
mainly rely on the coexpression or interactive relation of lncRNAs with other molecules, such 
as protein coding genes, miRNAs, and proteins. However, they do not take into account the 
importance of cancer mutations to the formation of lncRNA functions.  
 
Recently, Gonzalez-Perez‟ et al developed a novel approach, Oncodrive-fm, to identify cancer 
driver candidates. The rationale of Oncodrive-fm is cancer drivers tend to accumulate somatic 
mutations with high functional impact and any bias towards enrichment of variants with high 
functional impact indicates positive selection for the driver genes in the tumor. Oncodrive-fm 
(Gonzalez-Perez and Lopez-Bigas, 2012) applies SIFT, Polyphen2 and MutationAssessor to 
score the functional impact (FI) of each coding mutation, and calculates the average FI scores 
for the variants observed in each gene across all cancer samples. Cancer drivers display a shift 
toward accumulation of highly deleterious somatic mutations, therefore, they tend to have a 
high average FI score. For each gene and scoring system, Oncodrive-fm employs a 
Name Based on Cancer-
specific  
References 
Recurrent SCNAs -based Approach Recurrent somatic copy-number alterations (SCNAs) and 
differential expression of lncRNAs 
Yes 
(Du et al., 2013) 
Guttman et al ‘s coexpression based 
method 
Coexpression with coding genes and Gene Set Enrichment 
Analysis (GSEA) 
No 
(Guttman et 
al.,2009) 
a CNC network Coexpression with coding genes, gene ontology (GO) 
enrichment analysis and  
No 
(Liao et al., 2011)⁠ 
Liu et al‘s coexpression based method Coexpression with coding genes and  gene-disease associations No 
(Liu et al., 2014) 
Zhao et al ‘s co-expression network Coding-noncoding gene co-expression network Yes (Zhao,2014) 
Hao et al ‘s co-expression network Coding-noncoding gene co-expression network and differential 
expression 
Yes (Hao et al., 2015;. 
Hao,2015) 
lnc-GFP Gene expression and protein interaction and a global 
propagation algorithm 
No (Guo,2013) 
catRAPID RNA and protein interaction No (Bellucci,2011) 
miRcode Complementarity to seed regions and evolutionary conservation No (Jeggari,2012) 
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permutation test which randomly samples the same number of observed variants within the 
gene 1 million times and computes the average FI score for each sample, three P values are 
generated by comparing the average FI scores with a null distribution consisting of the 
1million average FI scores. Application of Oncodrive-fm to 135 glioblastoma multiforme 
samples identified that most of recurrently mutated genes such as TP53, PTEN, NF1, PIK3R1, 
ERBB2, EGFR, RB1, PIK3CA, also show a high ranking function impact bias.  
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Chapter 4 – A 
Permutation-based 
model for lncRNA 
driver search 
LI J,  Drubay D, Michiels S, Gautheret D 
 
Author contribution: 
Jia LI was the main contributor to this study, he performed the whole experiment under the 
supervision of Professor Daniel Gautheret. Drubay Damien and Michiels Stephan gave 
statistical support to the permutation-based model. Jia LI firstly wrote the manuscript, Daniel 
Gautheret gave his suggestion and comments and further revised the manuscript.   
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4.1 Introduction 
In the light of the pioneering study by Gonzalez-Perez (Gonzalez-Perez and Lopez-Bigas, 
2012), we hypothesized that cancer-associated lncRNAs would also display such a bias 
towards variants with functional impact. We implemented five different scoring systems to 
measure the function effect of non-coding variants: CADD, funSeq2, GWAVA, our SNP and 
SOM scores (Chapter 2). We applied a permutation- based model to prioritize cancer-
associated lncRNAs. For each lncRNA, the permutation-based model randomly takes the 
same number of observed variants and calculates the average functional scores 1 million times 
to form a null distribution and produces a P value via comparing the observed functional score 
to the null distribution. To further validate our hypothesis and the permutation model, we 
implemented the permutation model on 61 cancer-related lncRNAs and 547 cancer genes 
using cancer mutation data of liver cancer, lung cancer, CLL and melanoma. We observed 
experimentally validated cancer driver genes showed significantly higher positive selection 
and FI bias than non-cancer genes. Applying our permutation test to lncRNAs using five 
different scoring systems enabled us to prioritize hundreds of cancer-related lncRNA 
candidates for further experimental validation. We found our candidates show enrichment for 
evolutionary conserved regions and disease-causing variants. Furthermore, overall our 
approach opens the way to the detection of cancer-driving lncRNAs and non-coding elements 
of genes on a genome wide scale.  
  
4.2 Results 
4.2.1 Validation of the permutation-based model on cancer genes and lncRNAs 
We applied five different scoring systems to measure the function effect of non-coding 
variants: CADD, funSeq2, GWAVA, our SNP and SOM scores (Chapter 2). For each 
lncRNA and scoring system, the  permutation-based model randomly takes the same number 
of observed variants and calculates the average functional scores 1 million times to form a 
null distribution, a raw P value was generated via comparing the observed functional score to 
the null distribution. The raw P values from five independent permutation tests were adjusted 
using False Discovery Rate (FDR) (Yekutieli and Benjamini, 1999). Finally, we use z 
transform (Whitlock, 2005) to combine five different P values to form an uniform P value.  In 
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order to validate our permutation-based model, we applied it to 547 cancer-related protein-
coding genes annotated in the COSMIC database and 61 cancer-related lncRNAs manually 
curated from recent publications (Table S20). Cancer-related protein-coding genes have 
significantly lower adjusted positive selection P values than total genes (P value < 0.05 in all 
cases, Wilcoxon rank sum test, Figure 10A, Figure S8A , S9A, S10A, Table S7). Similarly, 
the adjusted P values of cancer-related lncRNAs are significantly lower than those of total 
lncRNAs (P value <0.05 in all cases except for the CADD model in CLL, Wilcoxon rank sum 
test, Figure 10B, Figure S8B , S9B, S10B, Table S7).  
We obtained the top 10 recurrently mutated genes (RMGs) for hepatocellular carcinoma, lung 
adenocarcinoma, Chronic lymphocytic leukaemia-small lymphocytic lymphoma and 
Malignant melanoma from the COSMIC database and analyzed their adjusted P values  
(Table 5, Table S8, S9, S10). If we consider for instance lung cancer, 40%, 100%, 60%, 80%, 
80% and 100% of RMGs show statistically significant results (adjusted P value < 0.05) using 
the CADD, funSeq2 , GWAVA, SNP, SOM and combined model respectively. SETBP1 was 
positively selected by all six models with significant statistical evidence (adjusted P value < 
0.05). EGFR, TP53, STK11, NF1, ZNF521 and GRIN2A had adjusted P values below 0.05 
by any five models (Table 5). Next, we ranked the adjusted P values computed by each model 
and found 10%, 80%, 10%, 50%, 50% and 80% of RMGs have the first ranking in CADD, 
funSeq2 , GWAVA, SNP, SOM and combined models respectively. The P values of ZNF521 
were ranked first by all but the SOM model. Three adjusted P values of funSeq2, SNP, SOM 
and combined models were ranked first for STK11, SETBP1, NF1 and SMARCA4. These 
results support the hypothesis that cancer-associated genes and lncRNAs display a bias 
towards accumulation of non-coding variants with high functional impact.  
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Figure 10. Distribution of adjusted P values for different gene classes. A. The comparison of 
adjusted P values computed by all permutation models between cancer-related genes and all genes; B. 
The comparison of adjusted P values computed by all permutation models between cancer-related 
lncRNAs and all lncRNAs. 
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Table 5. Adjusted P values and P value rankings of top 10 recurrently mutated genes in lung 
cancer 
RMG          CADD     FunSeq2               GWAVA           SNP          SOM Combined 
 Adjusted Pvalue (Ranking of P value) 
EGFR 0,6691(3569) 0,0000(1) 0,0003(16) 0,0024(567) 0(1) 0(1) 
TP53 0,0058(63) 0,0000(3) 0,7783(2741) 0,0095(1468) 0,0000(6) 0,0000(13) 
KRAS 0,4988(2318) 0,0067(1018) 0,1030(1326) 0,1159(3819) 0,0577(3379) 0,0000(1351) 
STK11 0,4653(2124) 0,0000(1) 0,0257(781) 0,0000(1) 0(1) 0(1) 
SETBP1 0,0043(49) 0,0000(1) 0,0001(5) 0,0000(1) 0(1) 0(1) 
SMARCA4 0,6627(3521) 0,0000(1) 0,5659(2400) 0,0000(1) 0(1) 0(1) 
NF1 0,0225(183) 0,0000(1) 0,6368(2514) 0,0000(1) 0(1) 0(1) 
CDKN2A 0,4503(2025) 0,0000(1) 0,0000(2) 1,0000(7507) 0,0017(824) 0(1) 
ZNF521 0,0000(1) 0,0000(1) 0,0000(1) 0,0000(1) 0,4097(4769) 0(1)  
GRIN2A 0,5151(2439) 0,0000(1) 0,0001(6) 0,0086(1383) 0,0024(994) 0(1) 
Number of 
unique P 
values 6123 7508 3168 7507 5175           
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4.2.2 General characteristics of driver candidates 
We ran the permutation-based method to prioritize cancer-related PC genes and lncRNAs, 
using 1,613,031 non-coding variants from the same lung cancer data as in Chapter 2. We 
define driver candidates as PC genes and lncRNAs whose adjusted P values are less than 0.05. 
Overall, 180 to 10403 lncRNAs and 595 to 12797 PC genes meet the selection criteria, 
depending on the scoring system used (Table 6, Table S11, S12, S13). Overall, the CADD 
model detected fewer driver candidates and their size was longer compared to driver 
candidates identified by other models. In contrast, the SOM model determined the highest 
number of candidates with the smallest length (Table 6, Table S11, S12, S13). Lastly, We 
found 122 gene and 14 lncRNA driver candidates common to five models in lung cancer, 103 
gene and 12 lncRNA driver candidates in liver cancer, 1 gene and 0 lncRNA driver candidates 
in CLL and 305 gene and 18 lncRNA driver candidates in melanoma (Figure11, Figure S11, 
S12, S13 and Table S14, S15, S16). There was higher overlap among candidates from the 5 
models as compared to random sampled ones (P=0 except lncRNA driver candidates for CLL, 
Table S17).  
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Table 6. General characteristics of PC gene and lncRNA driver candidates positively selected 
by each model in lung cancer 
Tool Adjusted P values < 0.05  
Number of genes (Mb) 
Average length (bp) 
 PCgene LncRNA PCgene LncRNA 
CADD 595(167) 180(17) 281945 96180 
funSeq2 6779(679) 918(34) 100302 37671 
GWAVA 2144(228) 1482(46) 103931 31476 
SNP 7674(914) 976(52) 119191 54252 
SOM 12797(1018) 10403(249) 79601 24001 
Combined 11417(887) 5716(162) 77693 28443 
Total Genes 20300(1266) 38263(456) 62412 11917 
 
Figure 11. Comparison of driver candidates detected by five independent permutation models.  A. 
Overlap of the driver gene candidates predicted by the 5 permutation models (CADD, FunSeq2, 
GWAVA, SNP and SOM); B. Overlap of lncRNA driver candidates predicted by the 5 permutation 
models (CADD, FunSeq2, GWAVA, SNP and SOM). 
4.2.3 LncRNA driver candidates harboring enriched conserved elements 
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The evolutionary conservation of lncRNAs has been an ongoing subject of research, with 
several studies showing that lncRNAs are modestly conserved (Derrien, 2012, Necsulea, 2014, 
Guttman, 2010). We obtained evolutionarily conserved regions from the UCSC 46 
mammalian genome alignment (Phastcons score >177) and mapped them onto lncRNA driver 
candidates. We performed a permutation test that randomly sampled regions with the same 
size as lncRNA drivers 1000 times from the whole lncRNAs set and computed the enrichment 
of conserved regions for each case. A P-value was produced by comparing observed 
enrichment of conserved elements with those of 1000 simulated samples.  
 
 
Figure 12. Enrichment for evolutionarily conserved regions within different lncRNA driver candidates 
in the four cancer types. For each feature, enrichment is computed as an odds ratio as explained in 
Methods. Values for each cancer are represented by a dot of distinct color. The blue dashed line 
denotes the baseline of enrichment of conserved regions in lncRNAs  
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Overall, the lncRNA predicted as positively selected by all models except SOM harbored 
higher enrichment for conserved regions than the random samples (P value <0.05 in all cases, 
Figure 12, Table S18). Owing to the large number of lncRNAs prioritized by the SOM model, 
these candidates showed similar level of enrichment for conserved regions as random samples 
(P value > 0.05 in three cases, a permutation test, Figure12, Table S18). For instance TTN-
AS1 and HOXA-AS2, two lncRNAs which are positively selected by all models in lung 
cancer and show 41.05% and 42.54% of coverage of conserved regions respectively. In 
addition, these two lncRNAs are intensively overlapping with non-coding functional features, 
such as Dnase I hypersensitive clusters, H3K27ac, suggesting their function importance in 
lung cancer (Figure 13 - 14).  
 
Figure 13. Graphical display of functional features in lncRNA TTN-AS1 from Genome browser  
Mammal cons: conserved regions, Dnase Clusters: Dnase I hypersensitive clusters, Layered H3K27ac: 
H3K27ac 
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Figure 14. Graphical display of functional features in lncRNA HOXA-A2 from Genome browser 
(same legend as in Fig 13).  
 
4.2.4 LncRNA driver candidates enriched for disease-associated variants 
In order to further assess the functional importance of our lncRNA driver candidates, we 
analyzed their enrichment for HGMD and Clivariant disease-associated non-coding variants 
with the same permutation test as we did for the conservation analysis. Overall, we found 
11/24 cases showing significantly increased enrichment for HGMD disease mutations 
compared to the random samples (P value <0.05, a permutation test, Figure15A, Table S19).  
Moreover, significant enrichment for Clivariant disease-associated variants was observed for 
17/24 lncRNA driver candidates (P value <0.05, a permutation test, Figure15B, Table S19). 
These results suggest that, to a large extent, our lncRNA driver candidates are enriched for 
non-coding disease-causing variants and further support their functional importance in the 
non-coding cancer genome. 
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 Figure 15. Enrichment for HGMD (A) and Clivariant (B) disease-causing variants within different 
lncRNA driver candidates in the four cancer types. For each feature, enrichment is computed as an 
odds ratio as explained in Methods. Values for each cancer are represented by a dot of distinct color. 
The blue dashed line denotes the baseline of enrichment of disease-causing variants in lncRNAs. The 
asterisks represent lncRNA driver candidates don‟t have HGMD and Clivariant disease-causing 
variants, their enrichment values are calculated as log10 (0.4202) and log10 (0.9524) respectively.  
 
4.2.5 Expression analysis of lncRNAs in lung cancer 
To further reduce the scope of screened cancer lncRNAs, we obtained RNA-seq data of 
normal lung and 85 cancer samples from Ju et al. (2012). 2208 lncRNAs were determined by 
DESeq2 Release (3.0) (Love et al., 2014) as differentially expressed between tumor and 
normal lung tissues with cutoffs of false discovery rate (FDR) ≤10e-4 and absolute fold 
change ≥2 (Figure 16, see methods). Among differentially expressed lncRNAs, 5 CADD, 45 
funSeq2, 93 GWAVA, 54 SNP, 605 SOM and 335 combining drivers are differentially 
expressed between cancer and normal lung tissues. This list of lncRNAs will be potential 
driver candidates for experimental validation in lung cancer cells.   
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Figure 16. Heatmap showing normalized abundance of 2208 lncRNAs differentially expressed 
between lung cancer and normal lung tissues.  
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4.3 Discussion 
The prioritization of cancer-associated lncRNAs is always a challenging and difficult task, as  
the mechanisms by which lncRNAs function are diverse and complex, ranging from gene  
transcription regulation, interaction with microRNAs or proteins to alternative splicing   
(Gutschner,2012). Over the past decade, researchers preferentially focused on lncRNAs which  
showed strong expression correlation with surrounding protein coding genes or interactions   
with proteins or miRNAs. A handful of computational tools have been developed to clarify  
lncRNA functions. However, little attention has been paid to the functional impact of non- 
coding mutations within lncRNAs and their importance to interpret cancer-associated  
lncRNAs. In this study, we tried to resolve this problem based on a permutation-based model  
which screens potential cancer-associated lncRNAs displaying a shift towards accumulation  
of non-coding variants with high functional impact. We applied the model to both cancer  
genes and lncRNAs using their non-coding somatic mutations in 4 cancer types, the results  
obtained showed that both cancer genes and lncRNAs have significantly lower adjusted P  
values than generic protein coding genes and lncRNAs in all cases, strongly supporting the  
validity of our model. As demonstrated in the Gonzalez-Perez et al 's study, the coding  
regions of cancer drivers preferentially accumulate mutations with high functional impact, an  
important concept that we carry out further in this study by showing this functional bias is  
absolutely applicable to non-coding regions such as UTRs or introns. Most importantly,   
despite their lack of coding potential, cancer lncRNAs exhibit the same trend. 
 
In addition, we carried out a permutation model on the whole lncRNA dataset and obtained   
hundreds of cancer-related lncRNA candidates. Further characterization of these lncRNAs  
showed they are a subset of lncRNAs enriched for evolutionary conserved regions and  
disease-associated variants, highlighting their functional importance. We listed a handful of   
lncRNA candidates, such as TTN-AS1, HOXB-AS3 and HOXA-AS2. Not only do these  
lncRNAs contain high coverage of evolutionarily conserved regions, but also they are  
intensively overlapping with non-coding functional features, such as Dnase I hypersensitive   
clusters and open histone marks. The lncRNA HOXA cluster antisense RNA 2 (HOXA-AS2),  
located between the HOXA3 and HOXA4 genes, has been functionally characterized in  
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leukemia (Zhao et al., 2013) and gastric cancer (Xie et al., 2015). The knockdown of its   
expression reduced cell viability and induced cell apoptosis in NB4 promyelocytic leukemia  
cells possibly through TNF-related apoptosis-inducing ligand (TRAIL) pathway (Zhao et al.,  
2013). Moreover, HOXA-AS2 is aberrantly expressed and plays an oncogene role in gastric  
cancer, knockdown of HOXA-AS2 markedly suppressed gastric cells growth by initiating G1  
arrest and enhancing apoptosis in part through inhibiting P21, PLK3, and DDIT3 expression   
(Xie et al., 2015). However, further experimental validation is still needed for other cancer  
lncRNA candidates to characterize their functional roles in cancer. 
There still a lack of efficient bioinformatics tools to prioritize cancer-related lncRNAs on a 
whole genome scale. A contribution of this work is that it might greatly reduce the scope of 
screening cancer lncRNAs for oncology researchers, simply based on the mutation pattern and 
function information of non-coding mutations within lncRNAs. However, many concerns still 
exist, for example, the SOM scores are computed on a 1-Kb scale, the other 4 scoring systems  
have a nucleotide-level scoring precision, which leads to a large number of positively selected 
lncRNAs by SOM model and greatly increases false positive rate, therefore an improvement 
is still needed with respect to increasing the prediction accuracy of the SOM model and 
reducing the number of false positively selected lncRNAs. Alternatively, we could find a way 
to combine the SNP and SOM scores to form an uniform score and then use it in the 
permutation test. These will be our objectives in the future. 
 
4.4 Methods and materials 
4.4.1 Cancer mutation, disease-causing variants, lncRNAs and cancer gene and lncRNA 
data 
Somatic variants were collected from whole genome sequencing of paired cancer and normal 
tissues, obtained from two studies: 2,011,261 variants from 25 melanoma patients (Berger et 
al., 2012), 1,845,976 from 24 lung adenocarcinoma patients, 881,136 from 88 liver cancer 
patients and 59,993 from 28 chronic lymphocytic leukemia (CLL) patients (Lawrence et al., 
2013). Variants described as "substitution" or "indel" were both collected and are referred to 
collectively as mutations in the text.   
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Curated disease-related variants were obtained from the Clivariant (Version 2014/03/03,  
55,689 variants) (Landrum et al., 2014) and HGMD (Version 2014/04/14, 166,768 variants)  
databases (Stenson et al., 2009). After exclusion of coding positions we used 13,108 HGMD  
and 6045 Clivariant mutations. 
LncRNA annotation mainly comes from three different sources, Gencode v7 (Harrow J, 2012), 
Human Body Map lincRNAs (large intergenic non coding RNAs) and TUCPs (transcripts of 
uncertain coding potential) generated from 4 billion RNA-Seq reads across 24 tissues and cell 
types (Pj et al., 2012) as well as Refseq annotation (Pruitt et al., 2007). In total, there are 
38263 lncRNA annotations (456.01 Mb) collected from these three different databases. Lists 
of cancer genes were obtained as follows: cancer-related lncRNAs are 61 mammalian long 
non-coding transcripts identified from our literature search as experimentally associated with 
different cancer types (Table S20); protein-coding cancer genes are from the Cancer Gene 
census, available from COSMIC release V71 (http://cancer.sanger.ac.uk/cancergenome/ 
projects/census/) (Forbes et al., 2011a).  
4.4.2 Scoring non-coding variants 
In total, non-coding variants were scored using CADD (http://cadd.gs.washington.edu/), 
FunSeq2 (http://funseq2.gersteinlab.org/), GWAVA 
(https://www.sanger.ac.uk/sanger/StatGen_ Gwava) , SNP model and SOM models 
respectively for each cancer type, all the parameters were set to default. Of note, we used the 
“region” classifier of GWAVA which is trained using regulatory variants of HGMD and a 
random selection of SNVs from across the genome to measure function effect of non-coding 
variants. 
4.4.3 The permutation-based model 
The permutation-based model relies on the hypothesis that cancer-related lncRNAs display a 
bias toward accumulation of non-coding variants with high function impact. Take lncRNA A 
and lncRNA B as examples (Figure S14A): lncRNA A is more enriched with non-coding 
variants with high function impact as compared to lncRNA B, therefore, lncRNA A is more 
likely to be non_coding driver in cancer. The permutation-based model consists of two main 
steps. First, all non-coding variants are scored with CADD, FunSeq2, GWAVA, SNP model 
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and SOM model of lung cancer respectively, then the average scores are computed for each 
lncRNA based on the observed variants in that specific lncRNA; the second step is a 
permutation test to examine which lncRNAs exhibit a function impact bias. As for each 
lncRNA and scoring system, it randomly takes the same number of observed variants with 
replacement from all the non-coding variants found in all sequenced samples and computes 
the corresponding average score, this random sampling is repeated 1,000,000 times, 
generating a null distribution of average scores for each lncRNA and scoring system (Figure 
S14B). Empirical Pvalues represent the fraction of sampling average scores greater than the 
observed ones, however, as for the SOM score, P values refer to the fraction of sampling 
average scores less than the observed ones. The P values from five independent permutation 
tests are adjusted using False Discovery Rate (FDR) (Yekutieli and Benjamini, 1999). In 
addition, we also run the permutation-based model on PCgenes using their non-coding 
somatic mutations. Driver candidates are defined as PCgenes and lncRNAs whose adjusted P 
values are less than 0.05. Finally, we use a z transform (Whitlock, 2005) to combine five 
different P values of each PCgene and lncRNA to form an uniform P value.  
4.4.4 RNA-seq data processing and expression analyses of lncRNAs 
161 RNA-seq data including 76 normal lung samples and 85 cancer samples were obtained 
from Ju et al‟s study (Ju et al., 2012). Reads were mapped to the  hg19 genome using Star 
aligner (Dobin et al., 2013). Read counts were computed with bedtools v2.22.1 for each 
lncRNA (Quinlan and Hall, 2010); DESeq2 Release (3.0) (Love et al., 2014) was used to 
identify differentially expressed transcripts between tumor and normal pairs with cutoffs of 
false discovery rate (FDR)(Yekutieli and Benjamini, 1999) ≤10e-4 and absolute fold change 
≥2. 
4.4.5 Enrichment analysis 
Enrichment for conserved regions or HGMD and Clivariant disease-associated variants within 
different driver candidate classes (Fig 12 and 15) was measured as the odds ratio: 
               
(
  
  
)
(
  
  
)
 
Where Hf = size of conserved regions or the number of HGMD and Clivariant disease-
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associated variants within driver candidate, Sf = total size of driver candidate, Hg = size of 
conserved regions or the number of HGMD and Clivariant disease-associated variants in 
whole lncRNAs, Sg = total size of lncRNAs. The significance of enrichment or depletion was 
evaluated using a permutation test as follows: a set of positions of same size as the driver 
candidate (ie. 17.31 Mb) was randomly sampled from the whole lncRNAs set 1000 times, and 
in each random sample, enrichments were calculated for each driver candidate class. 
Enrichment for HGMD and Clivariant disease-associated variants was evaluated similarly. 
4.4.6 Statistical analyses 
Data were presented as mean, differences between different groups were drawn with the 
Fisher exact test and Wilcoxon rank sum test in R, P < 0.05 was regarded statistically 
significant and the null hypothesis was rejected.  
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Chapter 5 - 
Conclusion and 
perspectives 
  
90 
 
5.1 General conclusion 
Functional annotation of cancer mutations have been a consistent focus of cancer genomics 
studies. In the past, researchers preferentially focused on mutations in the coding fraction of 
human genome. Ample bioinformatics tools have been developed to distinguish cancer-driver 
mutations from neutral ones, such as SIFT, polyphen2 and MutationAssessor. As descried in 
detail in the introduction, these tools can be classified as three main groups, empirical, 
machine learning and hybrid approaches. The rationales of these programs lie in a variety of 
properties ranging from evolutionary conservation, physicochemical constraints, protein 
structures and curation of disease-associated mutations. Based on function information of 
coding mutations, the downstream work is searching for cancer driver genes that are critical to 
cancer formation and progression. The most common approach (ie MutSigCV and MuSiC) 
detects recurrently mutated genes as cancer-driving. However, as cancer drivers can also 
occur at a low frequency, new programs independent of cancer mutation frequency have been 
developed (ie Oncodrive-fm, OncodriveCLUST and InVEx).  
In recent years, as an increasing number of variants have been identified as disease-associated 
in the non-coding genome, interpreting non-coding cancer mutations has become an urgent 
task in cancer genomics studies. The completion of large projects, such as ENCODE, has 
made functional interpretation of cancer variants achievable. Multiple programs have been 
built based on this functional information. As described in the introduction part, these tools 
can be divided into empirical approach such as RegulomeDB, funSeq2 and machine learning 
model such as CAAD and GWAVA.  In Chapter 2 of this study, in order to functionally 
interpret non-coding mutations in cancer and eventually identify new cancer drivers, we took 
into account the dual selection forces acting on the tumor genome: (1) population and 
evolutionary constraints acting at germline level and (2) constraints resulting from the 
accelerated mutation background of the cancer tissue. To achieve this, we have developed two 
independent models, refered to as SNP and SOM models. Given a combination of features, 
the SNP model was constructed to predict expected fraction of rare SNPs using random forest 
model, the second SOM model was built to compute the expected mutation density for each 
1-Mb window with an array of feature types ranging from replication time, expression level, 
histone modifications to regulatory elements. We applied our two models to score these 
91 
 
disease-associated variants and a set of random control SNPs. Our results showed that the 
SNP and SOM models are capable of distinguishing Clinvariant and HGMD disease-causing 
mutations from neutral ones. In addition, we intersected high SNP scoring and low SOM 
scoring regions and obtained 56 Mb functionally important regions (referred to as 
hypomutated regions). This small portion of the human genome shows highest enrichment of 
disease-causing variants among intergenic, low SOM scoring, high SNP scoring and 
hypomutated regions, further supporting low somatic mutation areas and high ratio of rare 
SNPs regions are functionally relevant and can be used as a screen for prioritizing cancer-
related non-coding mutations. This study demonstrated that purifying selection as measured 
by fraction of rare SNPs and mutation density constraints are informative for the evaluation of 
functional impact of cancer mutations in the non-coding genome. Moreover, combination of 
the SNP and SOM models would fasciliate the prediction of disease mutations in the non-
coding genome. 
 
Another important part in my thesis (Chapter 4) was the application of the scoring tools 
CADD, funSeq2, GWAVA and our SNP and SOM scoring systems to prioritize cancer-
associated lncRNAs with a permutation-based algorithm. We hypothesized that accumulation 
of non-coding mutations with high function impact indicates a positive selection in cancer 
genome and cancer-related lncRNAs show a bias toward enrichment of high functional non-
coding variants. We implemented the permutation model on 61 cancer-related lncRNAs and 
452 cancer genes using cancer mutation data of liver cancer, lung cancer, CLL and melanoma. 
We observed that both cancer lncRNAs and genes had lower average adjusted P values than 
total lncRNAs and genes. These results suggest that cancer-related lncRNAs and genes are 
enriched for non-coding variants with high functional impact. Applying the permutation test 
to lncRNAs with five different scoring systems enabled us to prioritize hundreds to thousands 
cancer-related lncRNA candidates. We would recommend to combine the adjusted P value 
and ranking of the P value to prioritize potential cancer-related lncRNA candidates. 
Furthermore, if we focus on those lncRNA candidates which are positively selected by all five 
scoring systems, the number of cancer-related lncRNAs candidates could be reduced to 11 in 
lung cancer, 11 in liver cancer, 0 in CLL and 18 in melanoma. These lncRNA candidates can 
be used for experimental validation. For example, we could study their function role in cancer 
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cells via over-expression or silencing.  
Taken together, we have successfully developed two models, SNP and SOM, to measure the 
functional impact of non-coding variants in the cancer genome. Injecting these scoring 
systems to a permutation-based model enables us to prioritize cancer-associated lncRNAs on 
a genome scale. The completion of our project paves the way for further characterization of 
unknown cancer mutations and lncRNAs in the non-coding cancer genome.  
 
5.2 Perspectives 
5.2.1 Refinement of the SOM and SNP models 
Due to the sparse number of cancer mutations, the SOM model was built based on a 1-Mb 
window and the SOM scores were computed and averaged on a 1-Kb scale.  As more and 
more whole genome sequencing studies are ongoing, there will be an explosive increase in the 
number of publically available cancer mutations, which should enable us to construct the 
SOM model with 1-Kb window and should remarkably improves the prediction accuracy. In 
addition, an increased prediction accuracy of the SOM score will greatly reduce the number of 
cancer-related lncRNA candidates positively selected by the SOM model and diminish the 
false positive rate. Lastly, as an accumulating number of new functional features are produced, 
adding these features to the SNP and SOM models and retraining the two models will further 
refine their prediction capability. 
 
5.2.2 Integrating SNP and SOM scores to form a combined score  
As shown above, there exists a remarkable difference between the SNP and SOM scoring 
systems with respect to score range and the importance of predicting disease-causing variants. 
As we did not find a satisfying way to integrate the two scores, an important work for us will 
be to come up with a way to combine scores and apply the combined score to the 
permutation-based model, which should reduce the number of cancer-related lncRNA 
candidates prioritized by the SOM model and its negative impact on the combined P value in 
the future. 
5.2.3 Functional analysis of cancer lncRNA candidates  
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We have identified a list of cancer-specific lncRNAs as prioritized by our permutation-based 
model. There is plenty of future work on this basis, such as analyzing where these lncRNAs 
are expressed, what expression levels they have in cancers and what relations they have with 
surrounding genes. Most importantly, in order to clarify the functional potential of the 
positively selected lncRNAs, experimental validation is needed. Ectopic expression using 
lentiviral vector and siRNA-mediated knockdown should be conducted in cancer cells. Their 
effect on cellular proliferation, apoptosis and metastasis should be examined through MTT, 
flow cytometry, transwell and wound-healing assays, respectively. This work will be 
performed with our collaborators in Institut Curie.  
5.2.4 Setting up an user-friendly website  
The objective of our project was to develop a scoring system for measuring the function 
impact of non-coding variants and provide a program to screen the ncRNA transcriptome for 
potential cancer-associated lncRNAs based on somatic mutations. These goals have been in 
part achieved, but an important future work will be to construct a user-friendly interface, to 
enable submission of somatic mutation data and obtain their SNP and SOM scores. Moreover, 
users may also upload mutation data generated by whole genome sequencing of a cohort of 
cancer samples and obtain a list of potential cancer-related lncRNAs for further experimental 
characterization.  
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6.1 Supplementary Figures 
 
 
Figure S1.  Construction of the Somatic Mutation (SOM) model for lung cancer.  A. Relative density 
of somatic mutations from whole genome sequences of 24 lung cancer, associated to different genome 
features (see Methods for feature details). Mutation density is normalized so that the whole genome 
average has a mutation density of 1. PCgene: protein coding gene; CDS: coding sequence;  Exon.P , 
Intron.P, Exon.L,Intron.L are exon and intron of protein coding gene and lncRNA respectively; CR: 
conserved region; DNase: DNase I hypersensitive site; ECS: evolutionarily conserved structure;  
ncExon: non-coding exon; PCgene.HE, LncRNA.HE, PCgene.LE and LncRNA.LE are high expressed 
and low expressed protein coding gene and lncRNA; PCgene.early, LncRNA.early, PCgene.late and 
LncRNA.late are early and late replicated protein coding gene and lncRNA; cTFBS: conserved 
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transcription factor binding site; RR H,RR L,GC H,GC L,DNA.met H and DNA.met L are 1-Kb 
windows with high recombination rate (> 4.0), low recombination rate (< 0.5), high GC content 
(GC % > 50%), low GC content (GC%<30%), high DNA methylation (average value > 0.7245) and 
low DNA methylation (average value < 0.4062) respectively; Red and blue dotted lines: base lines 
from CDS and intergenic regions; B: Feature importance as measured by IncNodePurity. We only 
show here features that passed feature selection. C. Distribution of SOM scores for neutral SNPs and 
for clinical variants from two disease-causing variants databases Clivariant and HGMD. Neutral SNPs 
here are the SNPs with allele frequency higher than 0.01 from the 1000 Genome project, SOM scores 
were predicted by the random forest model and divided by the number of patients. D. Correlation of 
SOM score with densities of disease-causing variants. The purple dotted line shows cutoff used for 
defining low SOM score in lung cancer. 
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Figure S2. Construction of the Somatic Mutation (SOM) model for CLL. See Fig S1 for legend.  
 
 
Figure S3. Construction of the Somatic Mutation (SOM) model for melanoma. See Fig S1 for legend. 
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Figure S4. Enrichment for low SOM score (A) or high SOM score (B) positions within genome 
features in the four cancer types. Low (high) SOM score regions are defined as the 300M positions of 
the genome with lowest (highest) SOM score. For each feature, enrichment is computed as an odds 
ratio as explained in Methods. Shaded grey areas show enrichment ranges obtained from 1000 random 
permutations of the 300M positions (see Methods). Values for each cancer are represented by a dot of 
distinct color. The asterisks represent genome feature (Cent & Tel regions) doesn‟t overlap with low 
SOM regions, their enrichment values are calculated as log10 (0.2).  
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Figure S5. Relationship between SNP and SOM scores in lung cancer (A), CLL (B) and melanoma 
(C). Grey dots: 1 million random genome positions; cyan contour: HGMD disease-causing variant 
positions; red contour: Clivariant positions. The top and right curves show marginal distributions of 
SNP scores (top) and SOM scores (right) for random genome positions, HGMD and Clivariant 
disease-causing variants. SNP score cutoff=0.63 (100Mb above cutoff), SOM score cutoffs = 20.63, 
0.59 and 25.76 variants/Mb, defining areas below cutoff of  1186.45 Mb, 1236.51Mb and 1170.98Mb 
in lung cancer, CLL and melanoma, respectively. Hypomutated regions (bottom, right area) defined by 
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both cutoffs correspond to ~56Mb in each cancer type. 
 
Figure S6.  Effect of combining high SNP scores and low SOM scores in 4 cancer types (A: liver 
cancer, B: lung cancer, C: CLL, D: melanoma). For each chromosome, the size of intergenic, high 
SNP, low SOM and high SNP + low SOM regions, was calculated and numbers of disease-associated 
variants either from HGMD or Clivariant were counted. The boxplot shows densities of disease-
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associated variants in each type of region, chromosome by chromosome. Cutoffs for defining high 
SNP and low SOM are the same as in Fig 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Venn diagrams showing the distribution of genes covered by hypomutated (A) or 
hypermutated (B) positions, across the 4 cancer types. In each cancer type the 100 genes with the 
highest coverage by hyper/hypomutated regions is shown.  
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Figure S8. Distribution of adjusted P values for different gene classes in liver cancer. A. The 
comparison of adjusted P values computed by all permutation models between cancer-related genes 
and all genes; B. The comparison of adjusted P values computed by all permutation models between 
cancer-related lncRNAs and all lncRNAs. 
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Figure S9. Distribution of adjusted P values for different gene classes in CLL. See S8 for legend. 
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Figure S10. Distribution of adjusted P values for different gene classes in melanoma. See S8 for 
legend.  
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Figure S11. The comparison of driver candidates positively selected by five scoring tools in liver 
canccer. A. The overlap of the driver gene candidates predicted by the 5 permutation models (CADD, 
FunSeq2, GWAVA, SNP and SOM). B. The overlap of the lncRNA driver candidates predicted by the 
5 permutation models (CADD, FunSeq2, GWAVA, SNP and SOM) 
Figure S12. The comparison of driver candidates positively selected by five permutation models in 
CLL. See S11  for legend. 
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Figure S13. The comparison of driver candidates positively selected by five permutation models in 
melanoma. See S11 for legend. 
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Figure S14. Detection of lncRNAs under positive selection in cancer 
A. LncRNA A shows a higher enrichment of non-coding mutations with high function impact as 
compared to LncRNA B, indicating LncRNA A is under positive selection in cancer 
B. The graphical display of permutation-based model for identifying lncRNAs harboring non-coding 
mutations with high function impact. 
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6.2 Supplemental Tables 
 
Table S1. Uniform genomic features used in figures and SNP or SOM models.  
Name Description 
Extent 
(Mb) 
Reference Model 
UTR mRNA untranslated region 47.23 
Gencode 
v7(Harrow et al., 
2012) 
SNP+SOM 
CDS Coding sequence 35.34 Gencode SOM 
Exon.P Exon of protein coding gene 91.15 Gencode - 
Intron.P Intron of protein coding gene 1236.20 Gencode SNP+SOM 
PCgene Protein coding gene 1266.97 Gencode SOM 
lncRNA Long non-coding RNA 337.12 Gencode SOM 
Exon.L Exon of lncRNA 16.44 Gencode - 
Intron.L Intron of lncRNA 324.18 Gencode SNP+SOM 
ncExon Non coding exon 30.61 Gencode SNP+SOM 
Intergenic Intergenic region 1568.79 Gencode SOM 
5‟SS 5‟splicing site (10bp from the splicing site) 2.95 Gencode - 
3‟SS 3‟splicing site (50bp from the splicing site) 13.03 Gencode - 
GC content Fraction of G or C nucleotide per 1Mb window - 
UCSC (Karolchik 
et al., 2014) 
SOM 
GC H 1-kb windows with high GC content (GC% > 50) 308.86 UCSC - 
GC L 1-kb windows with low GC content (GC% < 30) 104.89 UCSC - 
Promoter Promoter 84.91 Gencode SNP+SOM 
Enhancer Enhancer 12.03 
FANTOM5(Ander
sson et al., 2014) 
SNP 
TFBS Transcription factor binding site 947 
ENCODE(Rosenbl
oom et al., 2013) 
SNP 
cTFBS Conserved transcription factor binding site 59.23 UCSC SNP+SOM 
Sensitive Khurana et al.'s region of high rate of rare SNP 9.21 
(Khurana et al., 
2013) 
SOM 
CR Conserved region (PhastCons 46 way)  150.98 UCSC SNP+SOM 
ECS Evolutionarily conserved RNA structure  199.68 
(Smith et al., 
2013) 
SNP+SOM 
DNase I DNase I hypersensitive site (any cell type) 388.42 ENCODE SNP+SOM 
HE Highly expressed gene/RNA (RPKM>20) in either cell line 635.78 ENCODE SNP 
LE Low expressed gene/RNA (RPKM<0.25) in either cell line 1002.47 ENCODE SNP 
ER Early replicated gene/RNA (EL ratio >1) in all cell lines  418.68 ENCODE SNP 
Recombination rate Recombination rate averaged per 1Mb window - 
HAPMAP 
(Altshuler et al., 
2010) 
SOM 
RR H 1-kb windows with high recombination rate (> 4.0) 117.55 HAPMAP SNP 
RR L 1-kb windows with low recombination rate (< 0.5) 1034.26 HAPMAP SNP 
GC G or C base for each nucleotide - UCSC SNP 
 
109 
 
 
Table S2. Cell-specific genomic features used in figures and SOM models. 
 
  Extent (Mb) of feature 
Name Description 
Hepg2 
(liver) 
A549 
(lung) 
K562 
(CLL) 
Nhdfad 
(melanoma) 
H3k4me1 H3k4me1 384.12 420.25 325.92 378.14 
H3k4me2 H3k4m2 174.18 203.29 135.32 228.49 
H3k4me3 H3k4me3 106.66 152.19 147.31 192.53 
H3k9ac H3k9ac 158.06 157.44 185.10 251.10 
H3k9me3 H3k9me3 559.11 942.29 924.53 834.50 
H3k27ac H3k27ac 130.21 174.38 146.05 353.92 
H3k27me3 H3k27me3 767.11 861.39 641.29 695.29 
H3k36me3 H3k36me3 511.89 705.49 499.00 611.44 
H3k79me2 H3k79me2 314.30 430.61 269.26 354.03 
H3K20me1 H3K20me1 605.41 753.80 772.78 499.01 
H2az H2az 886.95 503.30 341.67 454.64 
CTCF CTCF 77.77 118.31 127.48 98.23 
Ezh2 Ezh2 698.22 - 871.32 435.09 
TFBS 
Transcription factor 
binding site 
286.38 164.61 348.46 65.69 
Expression level 
RPKM per 1Mb 
window 
- - - - 
PCgene.HE 
Highly expressed 
protein coding gene 
(RPKM >20) 
93.08 72.36 101.08 79.21 
PCgene.LE 
 
Low expressed 
protein coding gene 
(RPKM <0.25) 
422.35 222.52 457.92 311.64 
LncRNA.HE 
Highly expressed 
lncRNA (RPKM >20) 
21.34 23.70 22.49 22.08 
LncRNA.LE 
Low expressed 
lncRNA (RPKM 
<0.25) 
165.66 91.92 176.40 125.67 
  Hepg2 Imr90 K562 Bg02 
Replication time 
Replication timing 
ratio per 1Mb window  
- - - - 
LncRNA.early 
Early replicated 
lncRNA (E/L 
ratio >1) 
818.79 733.59 758.60 790.78 
LncRNA.late 
Late replicated 
lncRNA (E/L ratio 
<1) 
441.3 520.16 497.73 471.30 
PCgene.late 
Late replicated 
protein coding gene 
(E/L ratio >1) 
140.59 142.04 132.01 125.22 
PCgene.early 
Early replicated 
protein coding gene 
(E/L ratio <1) 
182.39 175.87 188.71 198.26 
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Liver hepatocelluar 
carcinoma 
Lung 
adenocarcinoma 
Acute myeloid 
leukemia 
Skin cutaneous 
melanoma 
DNA.met H 
Average DNA 
methylation value < 
0.4062 
58.22 63.96 99.81 68.14 
DNA.met L 
Average DNA 
methylation value > 
0.7245 
58.22 57.26 51.85 52.38 
 
Table S3. Significance of disease mutation enrichment in high-SNP+low SOM regions, for 4 
cancer types.   
 
Cancer type Region Region size (nt) HGMD Clivariant P value (1) 
- Intergenic 1568807082 913 213  
- High SNP 98163148 6784 1767  
Liver Low SOM 1255672000 9719 4572  
 Low SOM+ high 
SNP 
56198409 5079 1393 <2.2e-16 
Lung Low SOM 1186445000 9714 4596  
 Low SOM+ high 
SNP 
56160584 5012 1391 <2.2e-16 
CLL Low SOM 1236512000 9580 4660  
 Low SOM+ high 
SNP 
56267795 4773 1332 <2.2e-16 
Melanoma Low SOM 1170977000 9265 4384  
 Low SOM+ high 
SNP 
56148149 4892 1322 <2.2e-16 
 
(1) P values are computed as follows: disease-associated variants from the HGMD or 
Clivariant database are counted in high SNP or low SOM vs. Low SOM+high SNP regions, 
along with region sizes, forming a 2x2 matrix for Chi-square test in each cancer type. P values 
here are statistical significance for both HGMD and Clivariant databases. 
 
Table S4. Significance of over-enrichment for hypomutated regions within cancer vs non-
cancer genes. Enrichment for hypomutated regions was computed as explained in Methods for 
each independent gene. Then for each gene class (protein-coding, lncRNA, miRNA), a 
Wilcoxon rank sum test was performed to compare enrichment factors in cancer genes (see 
111 
 
Methods for gene lists) and in all genes in the class.  
 
Gene type Cancer type P-value 
Protein-
coding 
(non-coding 
parts) Liver  1.44E-12 
 Lung  5.05E-14 
 CLL 5.22E-15 
 Melanoma <2.20E-16 
lncRNA Liver  0.838 
 Lung  0.158 
 CLL 0.705 
 Melanoma 0.903 
miRNA Liver  0.007 
 Lung  0.003 
 CLL 0.011 
 Melanoma 0.004 
 
Table S5: Biological process GO-term biases (1) in the 100 protein coding genes with highest 
coverage by hypermutated (high SNP-high SOM) positions (liver cancer and CLL). 
 
GO biological process complete # # expected Fold 
Enrichment 
+/-  P value (2) 
Liver cancer 
Unclassified 4272 17 18.88 .90 - 0.00E00 
transcription from RNA polymerase II promoter 781 19 3.45 > 5 + 1.04E-05 
gene expression 3825 41 16.91 2.43 + 5.55E-05 
cellular nitrogen compound metabolic process 5112 48 22.60 2.12 + 9.12E-05 
nucleobase-containing compound metabolic 
process 
4372 43 19.32 2.23 + 2.58E-04 
RNA metabolic process 3373 37 14.91 2.48 + 2.61E-04 
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nucleic acid metabolic process 3874 40 17.12 2.34 + 2.85E-04 
cellular nitrogen compound biosynthetic process 3407 37 15.06 2.46 + 3.42E-04 
nucleobase-containing compound biosynthetic 
process 
2962 34 13.09 2.60 + 4.21E-04 
RNA biosynthetic process 2680 32 11.85 2.70 + 5.01E-04 
transcription, DNA-templated 2560 31 11.32 2.74 + 6.41E-04 
nucleic acid-templated transcription 2561 31 11.32 2.74 + 6.47E-04 
heterocycle biosynthetic process 3043 34 13.45 2.53 + 8.19E-04 
aromatic compound biosynthetic process 3044 34 13.45 2.53 + 8.25E-04 
nitrogen compound metabolic process 5475 48 24.20 1.98 + 9.12E-04 
Chronic lymphocytic leukemia (CLL) 
positive regulation of transcription from RNA 
polymerase II promoter 
987 17 4.46 3.81 + 1.52E-02 
 
Table S6. Mammalian long non-coding RNAs experimentally shown to be associated with 
different cancer types from a literature search.   
 
Chromosome Start End LncRNA Size(bp) Reference 
chr9 21994789 22029563 ANRIL 503 (Kotake et al., 2011) 
chr1 173833038 173837125 GAS5 632 (M. Sun et al., 2014) 
chr12 54356095 54362515 HOTAIR 2337 (Gupta et al., 2010) 
chr7 27135712 27139585 HOTAIRM1 483 (X. Zhang et al., 2014) 
chr6 8652441 8654459 HULC 500 (Panzitt et al., 2007) 
chr3 116428634 116435887 LOC285194 2105 (Qian Liu et al., 2013) 
chr3 50137035 50138421 LUST 1386 (Rintala-Maki and 
Sutherland, 2009) 
chr6 136265388 136282959 NTT 17572 (Delgado André and De 
Lucca, 2008) 
chr9 79379353 79402465 PCA3 3735 (Gezer et al., 2015) 
chr8 128025398 128033259 PCAT1 1992 (Prensner et al., 2011) 
chr2 193614570 193641625 PCGEM1 1590 (L. Yang et al., 2013) 
chr9 33673501 33677418 PTENP1 3932 (C.-L. Chen et al., 2015) 
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chr3 181417385 181433076 Sox2ot 2970 (Askarian-Amiri et al., 
2014) 
chr5 139929652 139937678 SRA 1965 (Leygue et al., 1999) 
chr22 31365633 31375381 TUG1 7105 (E. Zhang et al., 2014) 
chr19 15939756 15946230 UCA1 1413 (C. Yang et al., 2012) 
chrX 73040494 73072588 XIST 19271 (McHugh et al., 2015) 
chr8 128092118 128104845 PRNCR1 12756 (L. Yang et al., 2013) 
chr14 101292444 101327363 MEG3 1855 (Benetatos et al., 2011) 
chr11 2016405 2019065 H19 2308 (Fellig et al., 2005) 
chr11 65265232 65273940 MALAT1 8708 (Ji et al., 2003) 
chr14 61283510 61285560 HIF1A-AS2 2050 (W. Chen et al., 2015) 
chr17 23111183 23134213 Anti-NOS2A 23 (Korneev et al., 2008) 
chr7 148315552 148317449 GHET1 1898 (F. Yang et al., 2014) 
chr20 5048232 5048615 PCNA-AS1 384 (Yuan et al., 2014) 
 
Table S7. Significance of adjusted CADD, combined, funSeq2, GWAVA, SNP and SOM P 
values between cancer genes and protein coding genes, cancer lncRNAs and lncRNAs for 4 
cancer types.   
 
Comparison Cancer type CADD Combined FunSeq2 GWAVA SNP SOM 
Cancer 
gene VS 
PCgene 
Liver cancer 1,77E-039 4,91E-034 1,70E-089 3,69E-030 2,61E-029 1,05E-012 
Lung cancer 2,23E-044 1,43E-027 4,97E-094 2,60E-035 1,50E-022 6,98E-011 
   CLL 
3,17E-015 3,46E-016 9,09E-034 6,14E-021 1,21E-008 5,46E-005 
Melanoma 
4,62E-044 3,48E-032 7,73E-092 6,70E-032 7,16E-025 2,95E-013 
Cancer 
lncRNA 
VS 
lncRNA 
Liver cancer 1,07E-004 1,97E-008 4,74E-037 1,84E-019 2,21E-042 2,13E-003 
Lung cancer 1,91E-004 8,84E-006 2,17E-019 3,66E-013 1,20E-007 4,83E-004 
   CLL 
1,34E-001 3,34E-004 3,05E-049 1,72E-016 1,37E-030 4,69E-004 
Melanoma 
4,40E-002 5,09E-004 5,39E-004 1,29E-003 2,38E-019 2,30E-002 
P values are computed as follows: adjusted CADD, combined, funSeq2, GWAVA, SNP and 
SOM P values were compared with Wilcoxon rank sum test between cancer gene and protein 
coding genes, cancer lncRNAs and lncRNAs successively for each cancer type. 
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Table S8. Adjusted P values and P value rankings of top 10 recurrently mutated genes in liver 
cancer 
RMG CADD FunSeq2 GWAVA SNP SOM Combined 
 Adjusted P value (Ranking of P value) 
TP53 0,0000(1) 0,0000(1) 1,0000(2007) 0,0013(257) 0,0000(1) 0,0000(1) 
CTNNB1 0,6944(2748) 0,0000(1) 0,1135(857) 0,0001(10) 0,0001(40) 0,0000(1) 
TERT 1,0000(4953) 0,0786(2714) 1,0000(2007) 0,7601(6498) 0,0000(1) 0,0000(1) 
ARID1A 0,0644(229) 0,0000(1) 0,0000(1) 0,0000(1) 0,0000(1) 0,0000(1) 
HNF1A 0,6144(2150) 0,0070(884) 0,6690(1635) 0,2201(4272) 0,0000(3) 0,0000(1) 
AXIN1 0,3937(1106) 0,0435(2140) 1,0000(2007) 0,0144(1497) 0,0001(24) 0,0031(1866) 
ARID2 0,6259(2239) 0,1830(3668) 0,0000(1) 0,0000(1) 0,0000(1) 0,0000(1) 
IL6ST 0,7880(3435) 0,0000(2) 0,0520(637) 0,0097(1178) 0,0000(8) 0,0000(1) 
CDKN2A 0,6653(2543) 0,0001(13) 0,0778(739) 0,4164(5333) 0,3600(4717) 0,0005(1) 
ATM 0,3417(940) 0,0000(1) 0,0005(15) 0,0006(123) 0,0001(27) 0,0000(1) 
Number of 
unique P 
values 4953 6632 2007 7300 5406 7496 
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Table S9. Adjusted P values and P value rankings of top 10 recurrently mutated genes in CLL 
RMG CADD FunSeq2 GWAVA SNP SOM Combined 
 Adjusted Pvalue (Ranking of P value) 
MED12 0,9064(466) 0,2413(553) 0,3710(73) 0,0489(138) 0,0784(1038) 0,0049(457) 
POT1 0,7223(180) 0,1020(308) 1,0000(190) 0,3209(667) 0,5267(1825) 0,2263(1343) 
BCL11B 0,6437(112) 0,1570(421) 0,1986(37) 0,1191(313) 0,0927(1133) 0,0004(220) 
EGFR 0,8260(335) 0,0023(26) 0,8373(155) 0,4373(837) 0,0265(551) 0,0033(400) 
BCOR 0,7224(181) 0,2678(584) 0,8505(157) 0,0702(198) 0,1142(1231) 0,0100(558) 
ROS1 0,7468(207) 0,2714(591) 1,0000(190) 0,5062(923) 0,1796(1468) 0,2328(1358) 
Number of 
unique P 
values 627 1118 190 1279 2003 1974 
 
Table S10. Adjusted P values and P value rankings of top 10 recurrently mutated genes in 
melanoma 
RMG CADD FunSeq2 GWAVA SNP SOM Combined 
 Adjusted Pvalue (Ranking of P value) 
BRAF 0,0539(641) 0,0000(1) 0,0055(286) 0,0000(1) 0,0000(1) 0,0000(1) 
TP53 0,2796(2179) 0,0001(25) 0,3713(1756) 0,0022(584) 0,0000(1) 0,0000(1) 
ARID2 0,2101(1635) 0,0805(3337) 0,0003(17) 0,0000(1) 0,0000(1) 0,0000(1) 
ARID1A 0,0281(415) 0,0000(1) 0,0001(3) 0,0000(1) 0,0000(1) 0,0000(1) 
MAP2K1 0,5142(4061) 0,0000(1) 0,7810(2301) 0,0000(1) 0,0000(1) 0,0000(1) 
FGFR3 0,3749(2864) 0,0000(2) 1,0000(2575) 1,0000(7616) 0,0001(30) 0,0038(3224) 
BCL9 0,2414(1862) 0,1017(3587) 0,4900(1925) 0,0000(1) 0,0001(23) 0,0000(1) 
NCOA1 0,3326(2568) 0,0000(1) 0,0006(34) 0,0000(1) 0,0000(1) 0,0000(1) 
PAX3 0,0216(348) 0,0000(1) 1,0000(2575) 0,0038(846) 0,0049(1288) 0,0000(1) 
TPM3 0,1027(986) 0,0000(1) 0,0012(82) 0,0000(1) 0,0000(1) 0,0000(1) 
Number of 
unique P 
values 7752 7409 2575 7616 6482 7218 
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Table S11.the driver candidates of PCgenes and lncRNAs positively selected by each model 
in liver cancer 
Tool Adjusted P values < 0.05  
Number of genes (Mb) 
Average length (bp) 
 PCgene LncRNA PCgene LncRNA 
CADD 366(103) 234(19) 283679 83942 
funSeq2 5237(589) 395(21) 112575 55171 
GWAVA 1903(214) 401(23) 112642 58917 
SNP 6133(780) 237(22) 127337 95182 
SOM 10958(880) 6605(187) 80390 28412 
Combined 9739(867) 2821(113) 89113 40170 
Total Genes 20300(1266) 38263(456) 62412 11917 
 
Table S12.the driver candidates of PCgenes and lncRNAs positively selected by each model 
in CLL 
Tool Adjusted P values < 0.05  
Number of genes (Mb) 
Average length (bp) 
 PCgene LncRNA PCgene LncRNA 
CADD 5(1) 3(0.54) 210741 180329 
funSeq2 312(130) 24(1) 416712 47786 
GWAVA 12(4) 2(0.14) 337753 69675 
SNP 268(115) 3(0.33) 432029 109058 
SOM 1418(330) 148(22) 232755 154102 
Combined 1144(307) 94(113) 268402 106835 
Total Genes 20300(1266) 38263(456) 62412 11917 
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Table S13.the driver candidates of PCgenes and lncRNAs positively selected by each model 
in melanoma 
Tool Adjusted P values < 0.05  
Number of genes (Mb) 
Average length (bp) 
 PCgene LncRNA PCgene LncRNA 
CADD 1173(238) 501(34) 202996 69450 
funSeq2 7539(701) 984(35) 93109 35929 
GWAVA 2491(282) 2137(59) 96088 27912 
SNP 8404(942) 1000(52) 112206 52286 
SOM 11451(883) 9057(195) 77119 21606 
Combined 11322(852) 5066(129) 75323 25611 
Total Genes 20300(1266) 38263(456) 62412 11917 
Table S14.LncRNA driver candidates common to five permutation models in lung cancer  
Chrom
osome 
Start End LncRNA CADD FunSe
q2 
GWA
VA 
SNP SOM Combi
ned 
chr17 46667781 46683774 HOXB-AS3 0,0325 0,0001 0,0072 0,0093 0,0001 0,0000 
chr1 245003940 245018799 HNRNPU-AS1 0,0412 0,0012 0,0000 0,0000 0,0006 0,0000 
chr11 57479994 57586652 TMX2-CTNND1 0,0279 0,0000 0,0004 0,0000 0,0000 0,0000 
chr2 179385910 179639402 TTN-AS1 0,0000 0,0000 0,0000 0,0069 0,0000 0,0000 
chr2 144433734 144498863 RP11-434H14.1 0,0000 0,0000 0,0000 0,0000 0,0109 0,0000 
chr7 27147396 27173921 HOXA-AS2 0,0103 0,0000 0,0068 0,0120 0,0000 0,0000 
chr12 54747474 54860814 LOC102724050 0,0144 0,0000 0,0000 0,0006 0,0000 0,0000 
chr12 54747576 54860769 RP11-753H16.5 0,0144 0,0000 0,0000 0,0006 0,0000 0,0000 
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chr2 179246804 179541009 MIR548N 0,0000 0,0000 0,0000 0,0036 0,0000 0,0000 
chr2 144052990 144238358 AC096558.1 0,0000 0,0000 0,0000 0,0000 0,0060 0,0000 
chr2 144053155 144329674 RP11-570L15.2 0,0000 0,0000 0,0000 0,0000 0,0002 0,0000 
 
Table S15.LncRNA driver candidates common to five permutation models in liver cancer  
Chromo
some 
Start End LncRNA CADD FunSeq2 GWAVA SNP SOM Combin
ed 
chr17 37558046 37562486 CTB-131K11.1 0,0361 0,0208 0,0281 0,0335 0,0099 0,0000 
chr1 155996957 156132001 MIR7851 0,0099 0,0000 0,0058 0,0010 0,0000 0,0000 
chr11 57479994 57586652 TMX2-CTNND1 0,0160 0,0125 0,0111 0,0310 0,0000 0,0000 
chr20 39726969 39766643 RP1-1J6.2 0,0442 0,0000 0,0000 0,0000 0,0000 0,0000 
chr20 39726633 39766640 PLCG1-AS1 0,0442 0,0000 0,0000 0,0000 0,0000 0,0000 
chr3 114172440 114238979 RP11-197K3.1 0,0017 0,0000 0,0000 0,0002 0,0056 0,0000 
chr3 114172439 114238979 LOC101929754 0,0017 0,0000 0,0000 0,0002 0,0056 0,0000 
chr3 99273152 99717059 MIR548G 0,0043 0,0008 0,0000 0,0000 0,0000 0,0000 
chr12 11944823 12079107 RNU6-19P 0,0256 0,0060 0,0014 0,0002 0,0000 0,0000 
chr2 179246804 179541009 MIR548N 0,0000 0,0000 0,0000 0,0459 0,0000 0,0000 
chr15 60771377 60922836 RP11-219B17.1 0,0014 0,0000 0,0000 0,0004 0,0000 0,0000 
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Table S16.LncRNA driver candidates common to five permutation models in melanoma 
Chromo
some 
Start End LncRNA CADD FunSeq2 GWA
VA 
SNP SOM Combined 
chr17 56402811 56493127 BZRAP1-AS1 0,0049 0,0000 0,0000 0,0002 0,0000 0,0000 
chr12 54656399 54672847 RP11-968A15.2 0,0181 0,0001 0,0019 0,0073 0,0177 0,0000 
chr7 27147396 27173921 HOXA-AS2 0,0000 0,0000 0,0000 0,0005 0,0000 0,0000 
chr20 39726969 39766643 RP1-1J6.2 0,0486 0,0000 0,0083 0,0000 0,0002 0,0000 
chr20 39726633 39766640 PLCG1-AS1 0,0486 0,0000 0,0083 0,0000 0,0002 0,0000 
chr15 72571208 72644135 RP11-106M3.3 0,0438 0,0117 0,0101 0,0463 0,0000 0,0000 
chr12 54670415 54738867 RP11-968A15.8 0,0124 0,0000 0,0000 0,0000 0,0000 0,0000 
chr1 243866159 243904123 RP11-370K11.1 0,0057 0,0000 0,0009 0,0001 0,0000 0,0000 
chr1 33452676 33498070 RP1-117O3.2 0,0289 0,0005 0,0312 0,0000 0,0000 0,0000 
chr17 41622153 41687706 RP11-392O1.4 0,0248 0,0000 0,0017 0,0000 0,0000 0,0000 
chr12 54747474 54860814 LOC102724050 0,0000 0,0000 0,0002 0,0032 0,0000 0,0000 
chr12 54747576 54860769 RP11-753H16.5 0,0000 0,0000 0,0002 0,0032 0,0000 0,0000 
chr2 144052990 144238358 AC096558.1 0,0000 0,0000 0,0026 0,0001 0,0000 0,0000 
chr1 23346640 23414551 RP1-184J9.2 0,0005 0,0000 0,0000 0,0000 0,0000 0,0000 
chr14 30637040 30766245 TCONS_00022407 0,0000 0,0009 0,0088 0,0167 0,0000 0,0000 
chr2 179385910 179639402 TTN-AS1 0,0440 0,0000 0,0006 0,0271 0,0010 0,0000 
chr15 60771377 60922836 RP11-219B17.1 0,0000 0,0000 0,0000 0,0046 0,0072 0,0000 
chr3 99273152 99717059 MIR548G 0,0020 0,0000 0,0000 0,0000 0,0000 0,0000 
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Table S17. Significance of overlap of CAAD, funSeq2, GWAVA, SNP and SOM driver 
candidates in 4 cancer types.   
Gene Liver cancer Lung cancer CLL Melanoma 
PC gene 0 0 0 0 
LncRNA 0 0 1 0 
The significance of overlap was computed for CAAD, funSeq2, GWAVA, SNP and SOM 
driver candidates in 4 cancer types using a permutation test as follows: the same number of 
protein coding genes or lncRNAs with the driver candidates was randomly sampled from the 
whole lncRNAs set 1000 times, the overlap was calculated for five random sampling genes or 
lncRNAs. Then a P value was generated via comparing the observed overlap of driver 
candidates with 1000 sampling ones. 
 
Table S18. Significance of enrichment of conserved regions for CAAD, combined, funSeq2, 
GWAVA, SNP and SOM lncRNA driver candidates in 4 cancer types.   
 
Cancer type CADD Combined FunSeq2 GWAVA SNP SOM 
Liver cancer 0 0 0 0 0 0.911 
Lung cancer 0 0 0 0 0 0.057 
   CLL 0,07 0 0.003 0.446 0.009 0.08 
Melanoma 0 0 0 0 0 0.028 
The enrichment of conserved regions was calculated as described in the method. The 
significance of enrichment of conserved regions was computed using a permutation test as 
follows: a set of positions of same size as the driver candidate (ie. 17.31 Mb) was randomly 
sampled from the whole lncRNAs set 1000 times, and in each random sample, enrichment 
was calculated for each driver candidate class. Then a P value was generated via comparing 
the observed enrichment of conserved regions with 1000 sampling ones. 
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Table S19. Significance of enrichment of HGMD and Clivariant disease-causing variants for 
CADD, combined, funSeq2, GWAVA, SNP and SOM lncRNA driver candidates in 4 cancer 
types.   
 
Disease 
mutation 
Cancer type CADD Combined FunSeq2 GWAVA SNP SOM 
HGMD Liver cancer 0 0 0 0 0 0 
Lung cancer 0.434 0 0.011 0.483 0.035 0.201 
   CLL 0.14 1 0.062 0.114 0.26 0.154 
Melanoma 0.565 0.002 0 0.235 0.108 0.11 
Clivariant Liver cancer 0 0 0 0 0 0 
Lung cancer 0.032 0.025 0.007 0.023 0.014 0.338 
   CLL 0.211 0.151 0.418 0.016 0.148 0.962 
Melanoma 0.115 0.007 0 0.009 0.016 0 
The enrichment of HGMD and Clivariant disease-causing variants was calculated as 
described in the method, the significance of enrichment of disease variants was computed 
using the same permutation test as S11 (See S19 for method). 
 
Table S20. 61 Mammalian long non-coding RNAs experimentally shown to be associated 
with different cancer types from a literature search. 
Chromosome Start End LncRNA Length(bp) 
chr14 101292444 101327363 MEG3 34919 
chr11 2016405 2019065 H19 2660 
chr11 65265232 65273940 MALAT1 8708 
chr14 61283510 61285560 HIF1A-AS2 2050 
chr17 23111183 23134213 NOS2A 23030 
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chr7 148315552 148317449 GHET1 1897 
chr9 21994789 22029563 ANRIL 34774 
chr1 173833038 173837125 GAS5 4087 
chr12 54356095 54362515 HOTAIR 6420 
chr7 27135712 27139585 HOTAIRM1 3873 
chr6 8652441 8654459 HULC 2018 
chr3 50137035 50138421 LUST 1386 
chr6 136265388 136282959 NTT 17571 
chr2 192749845 192776899 PCGEM1 27054 
chr5 139929652 139937678 SRA 8026 
chr22 31365633 31375381 TUG1 9748 
chrX 73040494 73072588 XIST 32094 
chr15 69463026 69571440 RP11-279F6.1 108414 
chr8 126847055 127021014 PCAT1 173959 
chr7 77657660 77697345 APTR 39685 
chr3 180989770 181836880 SOX2-OT 847110 
chr20 5119586 5119969 PCNA-AS1 383 
chr8 127079874 127092595 PRNCR1 12721 
chr21 36131767 36175815 PlncRNA-1 44048 
chr17 76557764 76565348 ncRAN 7584 
chr3 116921431 116932238 BC040587 10807 
chr9 33673504 33677499 PTENP1 3995 
chr7 27198575 27207259 HOTTIP 8684 
chr1 202810954 202812156 PCAN-R1 1202 
chr9 94555069 94568127 PCAN-R2 13058 
chr9 69296681 69307056 BANCR 10375 
chr19 15828947 15836321 UCA1 7374 
chr16 74701404 74702604 lncRNA-EBIC 1200 
chr17 42865922 42874369 AOC4P 8447 
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chr10 31206278 31320447 ZEB1-AS1 114169 
chr14 19858667 19941024 lnc-ATB 82357 
chr12 120941728 120980965 HNF1A-AS1 39237 
chr15 69463026 69571440 DRAIC 108414 
chr15 69592129 69695750 PCAT29 103621 
chr7 27193503 27200106 HOXA13 6603 
chr20 50040707 50041629 treRNA 922 
chr8 75223404 75278461 ESCCAL-1 55057 
chr20 56285239 56287836 NKILA 2597 
chr19 15828947 15836321 CUDR 7374 
chr6 36673621 36675126 PANDAR 1505 
chr20 30309310 30311212 INXS 1902 
chr10 4769152 4772545 uc002mbe.2 3393 
chr1 168873143 169056243 AK126698 183100 
chr18 57054559 57072119 lincRNA-RoR 17560 
chr3 116921431 116932238 BC040587 10807 
chr9 33673504 33677499 PTENP1 3995 
chr7 27198575 27207259 HOTTIP 8684 
chr1 202810954 202812156 PCAN-R1 1202 
chr9 94555069 94568127 PCAN-R2 13058 
chr9 69296681 69307056 BANCR 10375 
chr19 15828947 15836321 UCA1 7374 
chr16 74701404 74702604 lncRNA-EBIC 1200 
chr17 42865922 42874369 AOC4P 8447 
chr10 31206278 31320447 ZEB1-AS1 114169 
chr14 19858667 19941024 lnc-ATB 82357 
chr12 120941728 120980965 HNF1A-AS1 39237 
chr15 69463026 69571440 DRAIC 108414 
chr15 69592129 69695750 PCAT29 103621 
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chr7 27193503 27200106 HOXA13 6603 
chr20 50040707 50041629 treRNA 922 
chr8 75223404 75278461 ESCCAL-1 55057 
chr20 56285239 56287836 NKILA 2597 
chr19 15828947 15836321 CUDR 7374 
chr6 36673621 36675126 PANDAR 1505 
chr20 30309310 30311212 INXS 1902 
chr10 4769152 4772545 uc002mbe.2 3393 
chr1 168873143 169056243 AK126698 183100 
chr18 57054559 57072119 lincRNA-RoR 17560 
chr2 87455368 87606805 Linc00152 151437 
chr5 180829954 180831618 lncRNA-HEIH 1664 
chr9 76764436 76787569 DD3(PCA3) 23133 
chr5 141697199 141697887 SPRY4-IT1 688 
chr3 116709235 116723581 LOC285194 14346 
chr8 127890589 128101253 PVT1 210664 
chr5 140102922 140107643 MA-linc1 4721 
chr16 53071943 53073640 PR-lncRNA-1 1697 
chr9 139001797 139004427 PR-lncRNA-10 2630 
chr6 36632321 36635073 lincRNA-p21 2752 
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6.3 Supplemental Methods 
 
Random Forest Models 
The random forests (RF) approach involves producing multiple regression trees, which are 
then combined to make a single consensus prediction for a given observation (Breiman L, 
2001). We generated the SNP RF model and the SOM RF model using the randomForest R 
package. The RF model is composed of an aggregate collection of regression trees, each 
created from boostrapped training samples: each branch is selected from a random subset of a 
given number (denoted be mtry) of the input variables (data columns). The two main 
parameters are mtry and ntree, the number of trees in the forest.  We used the mean squared 
error (abbreviated MSE) as a measure of the prediction accuracy of the RF model. Two MSE 
error estimates are used in the validation procedure: the OOB error and the cross-validation 
error. An important feature of RFs is its use of out-of-bag (OOB) samples. An OOB sample is 
the set of observations which are not used for building the current tree, and can be used to 
estimate the MSE error; it can be shown that an OOB error estimate is almost identical to that 
obtained by K-fold cross-validation.  
RF models have the advantage of giving a summary of the importance of each variable based 
on the randomized variable selection process used to grow the RF. An estimation of variable 
importance is provided by IncNodePurity, which measures the decrease in tree node purity 
that results from all splits of a given variable over all trees. This measure can be used to rank 
variables by the strength of their relation to the response variable, for interpretation purposes.  
Model Calibration 
We first tuned the two parameters mtry and ntree of the RF method. Figure S15 shows the 
OOB error progression on 500 trees for random forests using different parameters mtry. MSE 
errors stabilize at about 400 trees, so we see that ntree=500 (default value) was sufficient to 
give good performance for the SNP model and for the SOM model.  
In a regression framework, the default value of mtry is [p/3] where p is the number of 
variables. The case mtry=p corresponds to bagging (or bootstrap aggregation), a general 
purpose procedure for reducing the variance of a statistical learning method. For the SNP data 
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we have p=18 and the default value of mtry is 5. Note that a larger mtry is best suited to the 
SNP and SOM data, according to the MSE error (Figure S15 and Figure S18). We considered 
the gain in MSE error was small enough for mtry greater than 7 for the SNP model and 10 for 
the liver cancer SOM model.   
Assessment of variable importance is performed using IncNodePurity, with larger values 
indicating more important variables. We examined the RF variable importances behavior for 
different values of ntree and mtry. In Figure S16 and Figure S19, a graphical representation of 
the variable importances is shown using 3 values of mtry (5 the default, 7 and 14 for SNP 
model, 10, 20 and 30 for SOM model of liver cancer) and two values of ntree (the 500 default 
and 1000). The magnitude of the variable importances is increased with larger values of mtry, 
but we get nearly the same order for all variables in every run of the procedure and with every 
value of mtry. Moreover, using a small value of mtry is preferred in the presence of correlated 
predictors. We chose mtry=7 for the SNP model and mtry=10 for the SOM models of liver 
cancer, lung cancer, CLL and melanoma, respectively, based on lower MSE errors and 
smaller mtry values (Figure S15 and Figure S18). 
Feature selection 
We used the R VSURF package to perform variable selection. The selection procedure is 
based on a ranking of the explanatory variables using the random forests score of importance 
and a stepwise ascending strategy (Genuer, 2010). The first step eliminates the noisy variables 
and the second step selects the variables leading to the smallest OOB error. One advantage in 
using the VSURF procedure lies in its robustness with respect to the choice of mtry and ntree.  
Model Validation 
RFs were grown with ntree=500 for all models. We used mtry=7 for the SNP model and 
mtry=10 for the SOM models. The SNP RF model was trained using 16 explanatory variables. 
The SOM RF models were estimated using 21, 22, 29 and 23 explanatory variables selected 
by VSURF for liver cancer, lung cancer, CLL and melanoma respectively. The validation of 
the two models is given in terms of MSE. We used 10-fold cross-validation to compute the 
prediction error. We compared the prediction error of the RF model to the prediction error 
obtained training a multiple regression linear model with the same input variables involved. 
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We see that RFs outperform a linear model for the SNP and cancer mutation data (Figure 
S17A and Figure S20A). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S15. MSE sensitivity to ntree and mtry (SNP model) 
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Figure S16. variable importance (lncNodePurity) sensitivity to ntree and mtry (red line: absolute 
value of minimum importance among all features in the SNP RF model) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S17. Validation of the SNP model. A. MSE for linear regression model (Lrm) and Random 
forest (RF) with 10-fold cross validation (SNP model); B. observed and predicted fraction of rare 
SNPs (AF < 0.01) with 10-fold cross validation; C. the number of variables remained in the RF model 
minimizes the OOB error; D. the default number of trees in the RF model minimizes the OOB error. 
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Figure S18. MSE sensitivity to ntree and mtry (SOM liver cancer model) 
 
 
Figure S19. variable importance (lncNodePurity) sensitivity to ntree and mtry (red line: the absolute 
value of minimum importance  among  all features in the SOM model of liver cancer) 
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Figure S20. Validation of the liver cancer SOM model. A.MSE for linear regression model (Lrm) 
and Random forest (RF) with 10-fold cross validation (SOM model); B. observed and predicted 
somatic mutation density divided by 88 patients with 10-fold cross validation; C. the number of 
variables remained in the RF model minimizes the OOB error; D. the number of trees in the RF model 
minimizing the OOB error. 
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